---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description. Covers Product description and Place of product in therapy. 391 evidence topics quoted from 218 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Under review; NDA submitted November 2026

> “Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression November 9, 2026”
> “today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD).”
> “Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD”
> “We look forward to continuing the review process, and we are focused on delivering COMP360 to patients as quickly as possible, subject to FDA approval.”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

<a id="topic-2.1.1-2"></a>

##### Launch: Anticipated in the first half of 2027

> “Deep commercial capabilities in place to enable successful launch execution and broad patient access with launch readiness on track for expected launch in H12027, subject to FDA approval”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

> “With the imminent completion of our NDA submission and the potential for a quick approval, we are executing with urgency and discipline to launch this much needed treatment in the first half of 2027.”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “On Track for COMP360 Launch in H1 2027, if FDA Approved”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Compass anticipates the launch of COMP360 in the first half of 2027 subject to FDA approval and following Drug Enforcement Administration, or DEA, rescheduling.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-2.1.1-3"></a>

##### FDA review timeline under the Commissioner's National Priority Voucher

> “The voucher sets a one-to-two-month review target for the FDA, so there's the potential for a very rapid approval.”
> “When you look back at the limited number of precedents, they are all very different, but that sometimes encompasses both an acceptance and a review period, but there is a reasonably wide distribution around a median of around 60 days.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Potential for accelerated review, approval and rescheduling, given the National Priority Voucher (NPV) which could shorten review times to 1-2 months”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “The voucher program aims to shorten review to one or two months after the final application is submitted, compared with the usual 10 to 12 months, while preserving FDA safety and efficacy standards.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

<a id="topic-2.1.1-4"></a>

##### Breakthrough Therapy designation, October 2018

> “has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for treatment-resistant depression”

Source: [COMPASS Pathways (2018)](https://ir.compasspathways.com/News--Events-/news/news-details/2018/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/default.aspx)

> “In 2018, we received Breakthrough Therapy designation from the U.S. Food and Drug Administration, or the FDA for COMP360 for the treatment of TRD.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-2.1.1-5"></a>

##### Rolling review and Commissioner's National Priority Voucher, April 2026

> “today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD).”
> “Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards.”

Source: [COMPASS Pathways rolling review and voucher release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx)

> “Following these data read-outs and discussions with the FDA, the FDA granted our request for a rolling review of our NDA, which is ongoing.”
> “In April 2026, the FDA issued a National Priority Voucher for COMP360 psilocybin treatment in TRD.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-2.1.1-6"></a>

##### UK Innovation Passport under the Innovative Licensing and Access Pathway

> “We received an Innovation Passport designation from the MHRA for COMP360 for the treatment of treatment-resistant depression.”
> “The Innovation Passport is the entry point to the UK's Innovative Licensing and Access Pathway, or ILAP, a scheme intended to accelerate the time to market and facilitate patient access in the UK to certain types of medicinal products in development that target a life-threatening or seriously debilitating condition, or where there is a significant patient or public health need in the UK.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-7"></a>

##### Federal rescheduling by the DEA required before marketing

> “COMP360, if approved in the United States, will require rescheduling by the DEA before it can be marketed.”
> “For any product containing psilocybin to be available for commercial marketing in the U.S., psilocybin and psilocin must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V.”
> “Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.”
> “If or when COMP360 receives FDA approval, we anticipate that the DEA will make a scheduling determination and place it in a schedule other than Schedule I in order for it to be prescribed to patients in the U.S.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-8"></a>

##### Executive Order 14401 on timely rescheduling and priority vouchers for psychedelic drugs

> “The Commissioner of Food and Drugs shall provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program.”
> “The Attorney General shall, in consultation with HHS, initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate under 21 U.S.C. 811, may proceed as quickly as practicable for such specific products that are ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act.”

Source: [White House (2026)](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/)

> “With today’s Executive Order including the potential for accelerated regulatory and rescheduling processes, should COMP360 be approved, we will be ready to make this treatment available to patients.”

Source: [COMPASS Pathways executive order release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Commends-White-House-Executive-Order-to-Accelerate-Research-and-Access-for-Psychedelic-Treatments/default.aspx)

> “The executive order was really focused on DEA rescheduling and how to expedite that beyond or faster than the 90-day statutory timeline that the DEA has.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.1-9"></a>

##### State rescheduling: over 93% of the U.S. population in states intending to reschedule within 30 days of federal action

> “But I also want to just add, in terms of timing, we also need to make sure we understand that after federal DEA reschedules, the states also need to reschedule.”
> “we now have over 93% of the U.S. population living in states that have stated that they intend to reschedule within 30 days after federal DEA.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Further, most state laws in the U.S. classify psilocybin and psilocin as Schedule I controlled substances.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-10"></a>

##### Pipeline: PIVOT, a Department of Veterans Affairs trial of COMP360 in veterans with TRD

> “announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial.”
> “The multi-site, double-blind, randomized controlled trial will enroll veterans diagnosed with TRD, with or without concurrent PTSD, and will compare outcomes between two different doses of COMP360 psilocybin with the option for a second open label administration four weeks after initial dose.”
> “Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity.”

Source: [COMPASS Pathways PIVOT release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Working-with-U-S--Department-of-Veterans-Affairs-for-Investigational-Study-of-Psilocybin/default.aspx)

> “The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.”

Source: [ClinicalTrials.gov NCT07226232](https://clinicaltrials.gov/study/NCT07226232)

<a id="topic-2.1.1-11"></a>

##### Pipeline: COMP 104, a phase 2 trial in recurrent major depressive disorder

> “Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.”

Source: [ClinicalTrials.gov NCT05733546](https://clinicaltrials.gov/study/NCT05733546)

<a id="topic-2.1.1-12"></a>

##### Pipeline: post-traumatic stress disorder, phase 2b/3 Redefine trial (COMP202)

> “In January 2026, the FDA accepted our IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “The primary efficacy endpoint is the change from baseline in CAPS-5 total severity score at Week 8.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder”

Source: [ClinicalTrials.gov NCT07570654](https://clinicaltrials.gov/study/NCT07570654)

> “But importantly, our very next indication is PTSD.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.1-13"></a>

##### Pipeline: anorexia nervosa, phase 2 trial reported August 2025

> “In August 2025, we reported data from a double-blind randomized controlled Phase 2 clinical trial investigating the safety and efficacy of COMP360 psilocybin in participants with anorexia nervosa.”
> “It was a multicenter study and enrolled 32 patients.”
> “This Phase 2 clinical trial evaluated COMP360 dosed at 25mg against a control arm of participants receiving COMP360 1mg.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-14"></a>

##### NDA submission within two weeks, November 2026, superseded in November 2026

> “Rolling New Drug Application (NDA) submission nearing completion, with rolling review underway. Final NDA submission will be filed in the next two weeks”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

<a id="topic-2.1.1-15"></a>

##### NDA submission completion in the fourth quarter of 2026, March to September 2026, superseded in November 2026

> “Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4”

Source: [COMPASS Pathways fourth quarter 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)

> “Rolling submission and initial review are underway, with some modules of the NDA submitted and on track to complete all modules in Q4”

Source: [COMPASS Pathways second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)

> “A rolling New Drug Application, or NDA, submission and initial review with the U.S. Food and Drug Administration, or FDA, is underway and final submission remains on track to be completed in Q4, 2026.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

> “Rolling NDA submission and review underway and final submission on track to be completed in Q4”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-2.1.1-16"></a>

##### State rescheduling: approximately 90% of the U.S. patient population, August 2026, superseded in November 2026

> “Continued proactive engagement with state-level stakeholders to facilitate timely post-approval rescheduling; currently, approximately 90% of the U.S. patient population live in states that intend to reschedule within 30 days after Federal DEA”

Source: [COMPASS Pathways second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)

<a id="topic-2.1.1-17"></a>

##### Launch readiness by the end of 2026, March and May 2026, superseded in August 2026

> “Compass is rapidly advancing commercial readiness efforts to be launch-ready by the end of 2026”

Source: [COMPASS Pathways fourth quarter 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)

> “Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year”

Source: [COMPASS Pathways first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/q12026pressrelease.htm)

<a id="topic-2.1.1-18"></a>

##### Acceleration of commercialization readiness by 9 to 12 months, November 2025, superseded in March 2026

> “Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission”
> “Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026”

Source: [COMPASS Pathways third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)

<a id="topic-2.1.1-19"></a>

##### Phase 3 data timing: COMP005 in the second quarter of 2025 and COMP006 in the second half of 2026, October 2024, superseded in November 2025

> “Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025”
> “COMP006 data will now be announced after 26-week time point, expected in the second half of 2026”

Source: [COMPASS Pathways third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/q32024pressrelease.htm)

<a id="topic-2.1.1-20"></a>

##### Phase 3 data timing: COMP005 in the fourth quarter of 2024 and COMP006 in mid-2025, August 2024, superseded in October 2024

> “Top-line pivotal COMP005 trial data is expected in the fourth quarter 2024 and COMP006 trial top-line primary endpoint is expected mid-2025.”

Source: [COMPASS Pathways second quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024033854/q22024pressrelease.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: COMPASS Pathways

> “Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin”
> “Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

<a id="topic-2.1.2.1-2"></a>

###### Formulation: polymorphic crystalline synthetic psilocybin

> “COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Crystalline drug substance”
> “Pharmaceutical-grade purity”
> “Identified from first reported large scale synthesis of psilocybin”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “COMP360 psilocybin was administered in this study, which is COMPASS Pathways’ proprietary pharmaceutical-grade synthetic psilocybin formulation that has been optimised for stability and purity.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.1-3"></a>

###### Therapeutic class: classic psychedelic, potentially first in class

> “COMP360 is an investigational, proprietary synthetic formulation of psilocybin for the treatment of mental health conditions with the potential to become the first FDA-approved classic psychedelic treatment”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD.”
> “Compass is leading the development of this new class of medicines with rigor and discipline, successfully completing the largest late-stage clinical program in psychedelic treatments.”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Oral capsule, self-administered under monitoring

> “Patient self-administers oral capsule, monitored by a licensed HCP during session”
> “Orally administered formulation”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Doses studied in the phase 2b trial: 25 mg, 10 mg, and 1 mg

> “we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-2.1.2.2-3"></a>

###### Dose evaluated for retreatment in phase 3: 25 mg

> “52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

<a id="topic-2.1.2.2-4"></a>

###### Capsule strength in investigator studies: 5 mg capsules given as five capsules

> “The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

> “COMP360 psilocybin and placebo were administered as five capsules, matched for appearance, weight, color, texture and smell.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### United States controlled substance schedule: Schedule I

> “Psilocybin and psilocin are categorized as Schedule I controlled substances under the CSA”
> “Therefore, while psilocybin and psilocin are Schedule I controlled substances, products approved by the FDA for medical use in the U.S. that contain psilocybin or psilocin should be placed in Schedules II-V”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “which contains Schedule I controlled substances and must be rescheduled before commercializing COMP360 psilocybin in the U.S.”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

<a id="topic-2.1.2.4-2"></a>

###### United Kingdom controlled drug classification: Class A and Schedule 1

> “In the UK, psilocybin and psilocin are considered Class A drugs under the Misuse of Drugs Act 1971, as amended, and as Schedule 1 drugs under the Misuse of Drugs Regulations 2001, as amended.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication sought in the NDA: treatment-resistant depression

> “today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD).”
> “TRD is a form of depression, distinguished from major depressive disorder (MDD), by its definition requiring an inadequate response to two or more courses of antidepressants of adequate dose and duration.”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

> “I mean, just a reminder, and I will hand to Lori, our indication is TRD, and that is fundamental to the value both to patients, providers, and the company.”
> “Madison, it might also just be worth noting that because we were studying treatment-resistant depression, we were required to study failures after two failures.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.5-2"></a>

###### Company definition of TRD as a subset of major depressive disorder

> “We believe that our COMP360 psilocybin treatment could offer a new approach to treatment of serious mental health conditions, including treatment-resistant depression, or TRD, which is a subset of major depressive disorder, or MDD, post-traumatic stress disorder, or PTSD, and potentially many other serious mental health conditions.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Psilocybin as a prodrug of psilocin, a partial agonist at serotonin receptors

> “At the molecular level, psilocybin is rapidly metabolized to its active metabolite psilocin, which is a partial agonist at several 5-hydroxytryptamine (serotonin) 2A, or 5-HT, receptors, also known as serotonin receptors, including 5-HT2A, 2C, and 1A receptors.”
> “In particular, many of the prominent acute effects of psilocybin, such as changes in emotion and cognition, are thought to be mediated by 5-HT2A receptor stimulation, an interpretation that is supported by the fact that blocking the 5-HT2A receptor prevents the psychedelic effects of psilocybin in humans.”
> “In contrast, psilocin is believed to initiate an antidepressant effect by directly activating this receptor.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor.”
> “Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored.”

Source: [Dodd et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35811423/)

<a id="topic-2.1.2.6.1-2"></a>

###### Downstream signaling and neuroplasticity

> “Activation of 5-HT2A receptors by agonist ligands such as psilocin can modulate a number of downstream signaling cascades to alter the structure and function of neurons, which are important signaling components of the CNS.”
> “The consequences of 5-HT receptor signaling cascades as modulated by psilocin include (i) changes in activation of neurons in the brain, (ii) neuroplasticity, and (iii) alteration of neurotransmitter release.”
> “In particular, the expression of immediate early genes, or IEGs, such as Early Growth Receptor-1, or EGR-1 and Early Growth Receptor-2, or EGR-2, is induced by psilocin.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### Absence of serotonin release or reuptake inhibition

> “Psilocybin and psilocin lack clinically significant inhibitor activity at monoamine reuptake pumps, such as SERT or VMAT-2, thus do not result in substantially increased intrasynaptic serotonin”
> “Due to minimal intrasynaptic serotonin release, psilocybin’s mechanism of action is unlikely, even in high doses, to result in serotonin toxicity”

Source: [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Brain 5-HT2A receptor occupancy and plasma psilocin

> “Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model.”
> “Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores.”
> “Occmax [95% CI] determined from this model was 76.6 [67.3; 88.0]%, EC50 [95% CI] was 1.95 [1.17; 3.15] μg/L, and R2 was 0.92”
> “Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.”

Source: [Madsen et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6785028/)

<a id="topic-2.1.2.6.2-2"></a>

###### Time course and dose dependence of subjective effects

> “Mean (± SD) durations of subjective effects were 5.6 ± 2.2 hours, 5.5 ± 1.6 hours, and 6.4 ± 2.2 hours”
> “The duration and intensity of subjective effects were dose-dependent.”
> “The plasma concentration-time curve of unconjugated psilocin is consistent with the within-subject effect-time curve as documented with PK-PD modeling in this study.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.6.2-3"></a>

###### Onset and resolution of acute effects with COMP360 in healthy participants

> “In total, 511 TEAEs were reported, with a median duration of 1.0 day; 67% of all TEAEs started and resolved on the day of administration.”
> “255 started on the administration day, 235 (92%) of which were resolved that day”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.6.2-4"></a>

###### Cardiovascular effects: blood pressure, heart rate, and QTc interval with COMP360

> “Transient elevations in systolic BP, diastolic BP, and HR were seen in most participants, with effects peaking 2 to 3 hours post-dose.”
> “However, there were limitations related to access of data that prevented review of all continuous BP data.”
> “The results from the cardiodynamic evaluation demonstrated that COMP360 has no clinically relevant effect on cardiac conduction but an effect on HR could not be excluded.”
> “The effect on the QTc interval was either small or negative and an effect on ΔΔQTcF exceeding 10 ms can be excluded”

Source: [ISRCTN ISRCTN17905443 basic results (2024)](https://www.isrctn.com/editorial/retrieveFile/65a8139b-10a3-4341-b7e1-d15edeb0ab8e/45481)

> “There were no clinically significant findings in vital signs.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

> “Physiologically, psilocybin is known to cause mild increases in blood pressure and heart rate”

Source: [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)

<a id="topic-2.1.2.6.2-5"></a>

###### Cognitive function and emotional processing after a single dose of COMP360

> “There were no clinically relevant between-group differences in CANTAB global composite score, CANTAB cognitive domain scores, or emotional processing scale scores.”
> “These results indicate that 10 mg and 25 mg doses of psilocybin were generally well tolerated when given to up to six participants simultaneously and did not have any detrimental short- or long-term effects on cognitive functioning or emotional processing.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.6.2-6"></a>

###### Preclinical and in vitro pharmacology of psilocin metabolites

> “Neither 4-HIAA nor 4-HTP showed relevant interactions at assessed 5-HT receptors.”
> “The major metabolite 4-HIAA and 4-HTP were inactive at human 5-HT receptors but the activity of oxidized psilocin metabolites and norpsilocin remain to be assessed.”

Source: [Thomann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption, dephosphorylation to psilocin, and distribution

> “Psilocybin is rapidly dephosphorylated to psilocin, which is absorbed with Tmax values ranging from 1.8 to 4 h following oral administration.”
> “One study reported psilocin bioavailability at 52.7 ± 20%.”
> “The volume of distribution was extensive, ranging from 277 ± 92 L to 1016 L, suggesting significant tissue distribution.”
> “Elimination half-life varied across studies, ranging from 1.5 to 4 h.”

Source: [Meshkat et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12030428/)

<a id="topic-2.1.2.6.3-2"></a>

###### Fixed oral doses of 15, 25, and 30 mg: maximal concentration, time to peak, and half-life

> “Mean (95% confidence interval) maximal psilocin concentrations were 11 ng/mL (10-13), 17 ng/mL (16-19), and 21 ng/mL (19-24) after the administration of 15, 25, and 30 mg psilocybin, respectively.”
> “Maximal concentrations were reached after an average of 2 hours.”
> “Elimination half-lives were 1.8 hours (1.7-2.0), 1.4 hours (1.2-1.7), and 1.8 hours (1.6-1.9) for 15, 25, and 30 mg psilocybin, respectively.”
> “Psilocin exhibited dose-proportional PKs.”
> “Body weight did not influence pharmacokinetics or the response to psilocybin.”
> “Neither plasma concentrations (Cmax or AUC values) nor subjective effects (Emax values) correlated significantly with body weight, BMI, GFR, or age.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.6.3-3"></a>

###### Weight-based escalating doses and equivalence of the 25 mg fixed dose

> “No psilocybin was found in plasma or urine, and renal clearance of intact psilocin accounted for less than 2% of the total clearance.”
> “The pharmacokinetics of psilocin were linear within the twofold range of doses, and the elimination half-life of psilocin was 3 h (standard deviation 1.1).”
> “An extended elimination phase in some subjects suggests hydrolysis of the psilocin glucuronide metabolite.”
> “Simulation of fixed doses using the pharmacokinetic parameters suggest that an oral dose of 25 mg should approximate the drug exposure of a 0.3 mg/kg oral dose of psilocybin.”

Source: [Brown et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28353056/)

<a id="topic-2.1.2.6.3-4"></a>

###### Metabolism: glucuronidation by UGT1A10 and UGT1A9

> “UGT1A10 exhibited the highest psilocin glucuronidation activity, whereas the activities of UGTs 1A9, 1A8, 1A7, and 1A6 were significantly lower.”
> “suggest that whereas psilocin may be subjected to extensive glucuronidation by UGT1A10 in the small intestine, UGT1A9 is likely the main contributor to its glucuronidation once it has been absorbed into the circulation.”

Source: [Manevski et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2835393/)

<a id="topic-2.1.2.6.3-5"></a>

###### Metabolism: monoamine oxidase A, CYP2D6, and CYP3A4

> “MAO-A transformed psilocin into minimal amounts of 4-HIAA and 4-HTP.”
> “However, the CYP2D6 genotype did not influence psilocin plasma concentrations in the investigated study population.”
> “In conclusion, MAO-A, CYP2D6, and CYP3A4 are involved in psilocin’s metabolism.”
> “CYP2D6 and CYP3A4 seem to be involved to a minor extent in psilocin’s metabolism.”

Source: [Thomann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/)

<a id="topic-2.1.2.6.3-6"></a>

###### Elimination in urine as psilocin glucuronide, 4-HIAA, and unconjugated psilocin

> “Of the orally administered psilocybin (9.9 mg or 48.7 μmol psilocin in the 15 mg dose or 19.9 mg or 97.3 μmol in the 30 mg dose), an average of 20% was eliminated in urine as psilocin glucuronide and 33% was eliminated as 4-HIAA.”
> “Only 1.5% of the orally administered psilocybin was eliminated in urine as unconjugated psychoactive psilocin within 24 hours.”
> “Combined, ~ 54% of the administered dose of psilocybin is excreted renally within 24 hours as 4-HIAA, free psilocin, or psilocin glucuronide.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.6.3-7"></a>

###### COMP360 single-dose pharmacokinetic and food-effect study in healthy volunteers

> “To investigate the PK of increasing doses of orally administered COMP360 (1 mg, 10 mg, 25 mg and 50 mg) in healthy volunteers in the single dose PK component.”
> “To investigate the PK of orally administered COMP360 (25 mg), following high-fat food intake relative to fasting conditions in the FE component.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

<a id="topic-2.1.2.6.3-8"></a>

###### COMP360 pharmacokinetics in recurrent major depressive disorder

> “Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.”
> “Plasma concentrations of psilocybin, psilocin, 4-hydroxyindoleacetic acid (4-HIAA) and psilocin-O-glucuronide post-COMP360 administration on Day 1”

Source: [ClinicalTrials.gov NCT05733546](https://clinicaltrials.gov/study/NCT05733546)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Participants aged 65 years and older in the phase 3 trials

| Trial and arm | Age, years, minimum and maximum | Age 65 years or older, n (%) |
| --- | --- | --- |
| COMP005, COMP360 25 mg (N=171) | “19, 77” | “15 (8.8)” |
| COMP005, placebo (N=87) | “22, 72” | “11 (12.6)” |
| COMP006, COMP360 25 mg (N=296) | “18, 79” | “29 (9.8)” |
| COMP006, COMP360 10 mg (N=142) | “19, 73” | “9 (6.3)” |
| COMP006, COMP360 1 mg (N=143) | “20, 75” | “13 (9.1)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Renal impairment

> “The small amount of psilocin renally excreted suggests that no dose reduction is needed for subjects with mild-moderate renal impairment.”

Source: [Brown et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28353056/)

> “The renal clearance of psilocin was 42 ± 30 mL/min.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.8-3"></a>

###### Hepatic and renal impairment: regulatory expectation for dedicated studies

> “Sponsors should evaluate the pharmacokinetics of a psychedelic drug in patients with impaired renal function and patients with impaired hepatic function to provide dose adjustment recommendations and inform labeling.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.8-4"></a>

###### Hepatic function, cardiovascular disease, and seizure disorders as exclusions in the COMP360 pharmacokinetic study

> “Participants with AST, ALT, gamma-glutamyl transferase (GGT) or total bilirubin levels ≥1.5 x the ULN at Screening (V1) or day -1 (V2).”
> “Current or previous medical history of any cardiovascular conditions.”
> “Current or previous medical history of epilepsy or the presence of other medical conditions associated with seizures or convulsions.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

<a id="topic-2.1.2.8-5"></a>

###### Pregnancy and breastfeeding

> “Women of childbearing potential who are pregnant, breastfeeding, or planning to conceive.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

> “women of childbearing potential not using adequate contraception; women who were pregnant or breastfeeding”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-2.1.2.8-6"></a>

###### Psychiatric and treatment-history exclusions in the phase 3 trials

> “Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)”
> “Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module”
> “Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)”
> “Psychiatric inpatient within the past 12 months prior to Screening”
> “Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-2.1.2.8-7"></a>

###### Regulatory expectation for representative trial populations

> “Trials should not unnecessarily exclude subjects who have certain health characteristics (e.g., age, treatment history, concurrent treatments, pregnancy) if these groups are intended to receive the treatment post-approval, but they should be appropriately stratified.”
> “Excluded populations may not be described in the approved indication in prescribing information.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Psilocybin

<a id="topic-2.1.2.9.1-1"></a>

###### Regulatory summary of interactions with antidepressants and lithium

> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for 3 weeks or more may reduce the subjective effects of psychedelic drugs.”
> “Use of tricyclic antidepressants or lithium for 3 weeks or more may potentiate the subjective effects of psychedelic drugs, creating a potential psychiatric safety concern.”
> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for less than 3 weeks may also potentiate the subjective effects of psychedelic drugs.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.9.1-2"></a>

###### SSRIs and SNRIs: attenuation of psilocybin effects in survey reports

> “In reports (n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41-0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44-0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2-0.39] (bupropion).”
> “SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant.”
> “This dampening effect may last as long as 3 months following antidepressant discontinuation.”

Source: [Gukasyan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37291890/)

<a id="topic-2.1.2.9.1-3"></a>

###### Escitalopram pretreatment before psilocybin 25 mg in healthy participants

> “Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin administration, or 14 days of placebo pretreatment before psilocybin administration.”
> “Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects of psilocybin compared with placebo pretreatment.”
> “Escitalopram did not alter the pharmacokinetics of psilocin.”
> “Further studies are needed with a longer antidepressant pretreatment time and patients with psychiatric disorders to further define interactions between antidepressants and psilocybin.”

Source: [Becker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9299061/)

<a id="topic-2.1.2.9.1-4"></a>

###### Ongoing SSRI treatment with COMP360 25 mg in treatment-resistant depression

> “There were meaningful improvements in depression severity from Baseline to Week 3, indicating that ongoing SSRI treatment did not inhibit the therapeutic potential of psilocybin.”
> “Taken together, these findings suggest that the pharmacological interactions necessary for psilocybin to take effect are not meaningfully compromised by SSRIs”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-2.1.2.9.1-5"></a>

###### Recent antidepressant discontinuation before COMP360 in the phase 2b trial

> “Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.”
> “Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-2.1.2.9.1-6"></a>

###### Chronic antidepressant exposure and 5-HT2A receptors in preclinical studies

> “More convincingly, chronic administration of antidepressant drugs, including a selective serotonin reuptake inhibitor (SSRI), reduced the head-twitch response, a stereotypic behavior exhibited by rodents in response to 5-HT2A agonizts and also downregulated 5-HT2A receptors, which are considered essential for the subjective psychedelic effects of psilocybin”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-2.1.2.9.1-7"></a>

###### Lithium and seizures

> “They found that 2 of the 6 reports of lithium plus psilocybin resulted in seizures.”
> “None of the 10 reports of lamotrigine plus psilocybin resulted in seizures.”

Source: [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)

<a id="topic-2.1.2.9.1-8"></a>

###### Monoamine oxidase inhibitors

> “Inhibition of psilocin inactivation by MAO could potentially augment the metabolic pathway catalyzed by CYP2D6, thereby altering the pharmacodynamics of psilocybin therapy.”
> “Moreover, glucuronidation of psilocin would likely continue to be the predominant metabolic pathway, rendering MAO inhibition potentially less important.”

Source: [Thomann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/)

<a id="topic-2.1.2.9.1-9"></a>

###### UGT1A9 and UGT1A10 inhibitors and estradiol

> “Diclofenac and probenecid are examples of UGT1A9/10 inhibitors that may hypothetically alter psilocybin metabolism if co-ingested; however, there is no evidence to confirm this hypothesis beyond shared metabolism.”
> “There are few pharmacologic agents that influence UGT1A9 and UGT1A10”
> “This suggests that hormone replacement therapy, oral contraceptives, and cyclical hormonal changes may affect the metabolism of psilocybin, highlighting the need for more inclusive research.”

Source: [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)

<a id="topic-2.1.2.9.1-10"></a>

###### Antipsychotics and 5-HT2A receptor antagonists

> “Haloperidol pretreatment reduced psilocybin effects on the Oceanic boundlessness, measures of derealisation and depersonalisation phenomena but increased anxiety without any effects on visual hallucinations or delayed response tasks.”
> “Risperidone pretreatment attenuated the effects of psilocybin in a dose-dependent manner.”
> “Ketanserin pretreatment blocked psilocybin effects in a dose-dependent manner on the delayed response task and Altered State of Consciousness Rating scale.”
> “Except for a few case reports, no serious adverse drug events were described in the included studies.”

Source: [Halman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/)

Additional sources: [Nayak et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34348413/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Psilocybin on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### In vitro inhibition of cytochrome P450 isoforms by psilocin

> “the obtained IC₅₀ values indicate that psilocin exhibits relevant inhibitory potential across several enzymes, acting as a moderate inhibitor of CYP3A4 and CYP2B6 and as a strong inhibitor of CYP2A6.”
> “The remaining compounds did not demonstrate significant inhibitory effects.”

Source: [Silva-Carvalho et al. (2026)](https://revistas.rcaap.pt/revsalus/article/view/46635)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Single 25 mg dose in COMP005 and two fixed doses in COMP006

> “Pivotal trial 1 (COMP005) (n=258): a single dose (25mg) monotherapy compared with placebo.”
> “Pivotal trial 2 (COMP006) (n=581): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg.”
> “This trial is designed to investigate whether a second dose can increase therapeutic response.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose response in the phase 2b trial

> “psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-2.1.2.10.1-3"></a>

###### Retreatment in Parts B and C of the phase 3 trials

> “During Part B, based on pre-specified criteria, participants were eligible either for a second administration of the treatment to which they were randomized or to resume antidepressants.”
> “During Part B, 70% of participants in the 25mg arm and 53% of participants in the placebo arm received a second administration.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Re-dosing for non-remitters from Part A or Part B could occur several weeks after transition to Part B or Part C, respectively, due to scheduling requirements.”
> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”
> “Findings provide further evidence of notable reduction in MADRS and prolonged durability that can be experienced with just two or three doses of 25mg COMP360 within a year”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.10.1-4"></a>

###### Dosing the company intends to seek in labeling

> “As we have said always, what we would envisage and target is after one or two initial administrations, that then there is the provision for episodic dosing per physician decision.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Label has not been determined as COMP360 is not yet approved by the FDA”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.10.1-5"></a>

###### Capsule strength and count in the phase 1 study

> “The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.10.1-6"></a>

###### Regulatory expectations for evaluating repeat dosing

> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”
> “The most informative clinical trial design would incorporate blinded long-term follow-up (typically 12 months) with prespecified criteria for retreatment.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Preparation, administration session of approximately six to eight hours, and post-administration follow-up

> “Our trial protocols provide that such support is delivered over three different phases: preparation, the COMP360 administration session, and post-administration follow-up.”
> “The objectives of the preparation sessions are to establish a therapeutic alliance between the patient and healthcare professional, and to demonstrate and practice the skills of self-directed inquiry and experiential processing, which we believe are critical for embracing the psychedelic experience in the psilocybin administration session.”
> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”
> “The objectives of the follow-up sessions are to help patients process the range of emotional and physical experiences facilitated by the psychedelic experience and to integrate any new insights that can lead to cognitive and behavioral changes.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.10.2-2"></a>

###### Session setting and discharge

> “The session takes place in a room designed to have a comfortable and calming ambience.”
> “Patients wear eye shades to help them focus internally, lie on a bed, and listen to a carefully curated music playlist through a high-quality sound system and earphones.”
> “After the acute effects of psilocybin subside, patients are evaluated for safety and discharged.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.10.2-3"></a>

###### Preparatory and follow-up sessions in the phase 2b trial

> “Prior to administration, participants received at least one, and up to three, preparatory sessions with an assigned healthcare professional, in order to be informed and prepared for the COMP360 psilocybin session.”
> “Participants received two post-administration follow-up sessions with their healthcare professionals in which the psychedelic experience was discussed.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.10.2-4"></a>

###### Compass Psychological Support Model and therapist training

> “The authors describe the Compass Psychological Support Model (CPSM), currently used to support participants with treatment-resistant depression in Compass-sponsored clinical trials of investigational COMP360 psilocybin treatment.”
> “The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery.”

Source: [Kirlić et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741434/)

> “The FDA currently requires all United States therapists to have at least a Masters' level of education and that two trained therapists are present for all psilocybin sessions.”

Source: [Tai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908919/)

<a id="topic-2.1.2.10.2-5"></a>

###### Support provided during administration sessions

> “The vast majority (78%) of the administration session was spent in silence.”
> “Support strategies include breath and body awareness, short verbal cues, and physical proximity.”

Source: [COMPASS Pathways support model publication release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx)

<a id="topic-2.1.2.10.2-6"></a>

###### Monitoring by healthcare professionals

> “Observation by two monitors for the duration of the treatment session.”
> “A health care provider with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently, serving as the lead monitor.”
> “An assistant monitor with a nursing or bachelor’s degree and at least 1 year of clinical experience in a licensed mental health care setting.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “our design matches what they have guided, which is to have one primary monitor and to use CCTV to assist with the total monitoring by two total healthcare providers”
> “like the six hours versus two hours requirement”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.10.2-7"></a>

###### Simultaneous dosing of several participants

> “administered simultaneously to up to six participants, with one-to-one psychological support – each participant having an assigned, dedicated therapist available throughout the session”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.10.2-8"></a>

###### Expected setting after approval

> “Patient self-administers oral capsule, monitored by a licensed HCP during session”
> “Dosing and monitoring to take place at a certified treatment center”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.10.2-9"></a>

###### Fasting and water intake in the COMP360 pharmacokinetic study

> “In the single ascending dose PK component and the fasted treatment period of the FE component, the study treatment will be administered following an overnight fast (at least 10 hours fast pre-dose).”
> “Each dose will be taken with 240 mL of water at room temperature.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

<a id="topic-2.1.2.10.2-10"></a>

###### Serotonergic antidepressant taper before dosing in the phase 2b trial

> “Participants who were on serotonergic medications were required to taper off their medicine at least two weeks prior to the baseline (Day -1) visit.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Risk Evaluation and Mitigation Strategy expected, modeled on the Spravato REMS

> “For instance, we believe that COMP360, if approved, would be subject to a REMS program, under the applicable FDA regulations.”
> “REMS programs are costly and time-consuming for providers to comply with, involving high administrative burden, which could delay or limit our ability to commercialize our investigational COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Again, we will not go into much detail on the REMS, but what we can say is what we have said publicly in the past, that the FDA directed us to use the SPRAVATO REMS as a template, and that would be where we see the direction going.”
> “It is extremely resource-intensive and complex, and we have an entire group at Compass who will help facilitate all of this.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-2"></a>

###### Prescriber and provider training

> “Based on our interactions with the FDA as we work towards finalizing our REMS, we expect there to be training content within the REMS that will take about one to two hours to review.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin.”
> “In all, five organizations were awarded the grant, expanded from the originally three recipients due to the overall quality of applicants”

Source: [COMPASS Pathways provider training grant release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-U-S--Grant-Program-Recipients-for-the-Development-of-Post-Approval-COMP360-Provider-Training/default.aspx)

<a id="topic-2.1.2.11-3"></a>

###### Administration at a certified treatment center with session monitoring

> “Prescribed by an HCP licensed to prescribe medication to patients”
> “Dosing and monitoring to take place at a certified treatment center”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Monitoring staffing: one primary monitor and closed-circuit television, two healthcare providers in total

> “If you look at the now finalized guidance from FDA for the design of clinical trials in psychedelics, our design matches what they have guided, which is to have one primary monitor and to use CCTV to assist with the total monitoring by two total healthcare providers.”
> “We are, as I mentioned earlier, still finalizing the REMS in discussion with FDA, but we would certainly anticipate that the final requirements will be no more stringent than what has been required so far in clinical trials.”
> “This happens to match the current staffing models that are used in the interventional psychiatry clinics delivering SPRAVATO today.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-5"></a>

###### Treatment-center network: more than 8,500 interventional psychiatry centers

> “COMP360 expected to fit seamlessly within an established and expanding infrastructure of more than 8,500 treatment centers”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “>8,500 Spravato® treatment clinics in US”
> “www.spravatohcp.com/find-treatment-center – data pulled 07/31/2026”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Seven years ago, when SPRAVATO launched, this infrastructure did not exist.”
> “Today, there are more than 8,500 interventional psychiatry treatment centers in place across the U.S., and it continues to grow rapidly.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-6"></a>

###### Distribution channels: specialty pharmacy and buy-and-bill, reimbursed through the pharmacy benefit

> “COMP360 expected to be available through specialty pharmacy and buy-and-bill”
> “drug reimbursed through pharmacy benefit.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “COMP360 will be available through both specialty pharmacy and buy-and-bill, with drug reimbursed through pharmacy benefit.”
> “Right now, we think and believe SPRAVATO buy-and-bill volume is somewhere in the 30%-40% range of volume.”
> “In terms of preference, just using that as a proxy, we don't believe that buy-and-bill will be huge for COMP360 out of the gate, but we expect it to ramp to something very similar to SPRAVATO, potentially even surpassing it.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-7"></a>

###### Monitoring billed through CPT Category III codes for psychedelic drug monitoring

> “CPTIII codes specifically for psychedelics”
> “billed by the hour through medical benefit”
> “Coding and reimbursement for COMP360 have not yet been established and are subject to change from current thinking”
> “CPT III codes accepted, and language released by AMA for Psychedelic Drug Monitoring Services; published in the CPT Manual and effective on January 1, 2024”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Ultimately, we anticipate that taking 12-18 months.”
> “But in the interim, as I said, sites will be supported to understand how they can code in the short term, and we will have patient support programs in place to ensure that affordability is not a barrier to access in the early days of the launch.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-8"></a>

###### Payer engagement, reimbursement assistance, and patient support

> “In addition, over the past quarter, our newly expanded team of medical science liaisons have continued to educate clinicians on TRD and COMP360, and our payer access team has been actively engaging with payers across regional and national accounts, as well as state-level plans.”
> “We will also have a dedicated team of specialists working directly with clinics to facilitate the logistics associated with reimbursement for both the drug and the monitoring time for COMP360 administration.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “At approval, our top priority is site and patient experience”
> “REMS certification”
> “Reimbursement assistance”
> “Patient support hub”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.11-9"></a>

###### Current reimbursement status of psilocybin as a Schedule I substance

> “Notwithstanding any of the above, as Schedule I substances under the Controlled Substances Act, psilocybin and psilocin are currently deemed to have no accepted medical use and therapies that use psilocybin or psilocin are currently precluded from reimbursement in the United States.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.11-10"></a>

###### Federal and state rescheduling as a precondition of prescribing and distribution

> “Our products must be scheduled as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V) before they can be commercially marketed.”
> “Facilities that manufacture, distribute, import or export any controlled substance must register annually with the DEA.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “So, that timing also needs to happen before a product can actually be prescribed and administered.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Discontinuation of prohibited medications before dosing in the phase 3 trials

> “At Screening, agreement to discontinue all prohibited medications.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Antidepressant discontinuation during screening in the phase 2b trial

> “Data from 233 participants with treatment-resistant depression (TRD) who received 25 mg, 10 mg, or 1 mg of investigational drug COMP360 psilocybin (a proprietary, pharmaceutical-grade synthetic psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.), administered with psychological support, were compared for groups of participants who either discontinued one or more antidepressant drugs during screening or entered the trial antidepressant drug free.”
> “Suicidality was comparable between groups at Baseline.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-2.1.2.12-3"></a>

###### Withdrawal of antidepressant, antipsychotic, and mood-stabilizing drugs in the PsiDeR trial

> “during which they were withdrawn from antidepressant, antipsychotic or mood-stabilizing drugs and had sessions of psychological preparation and psychoeducation with a trial therapist”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-2.1.2.12-4"></a>

###### Adjunctive SSRI: COMP360 25 mg with an ongoing SSRI

> “Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.”
> “All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.”
> “Twelve (63.2%) participants had a TEAE, most of which were mild and resolved on the day of onset.”
> “There were no serious TEAEs or indication of increased suicidal ideation or behavior.”
> “Larger, comparator-controlled trials are necessary to understand if this paradigm can optimize treatment-outcome where antidepressant drug withdrawal would be problematic.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

> “25mg COMP360 psilocybin treatment was generally well-tolerated when it was administered simultaneously with the patient’s existing SSRI treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.12-5"></a>

###### Adjunctive antidepressant permitted in the company's PTSD trial

> “In both Part A and Part B, COMP360 may be administered adjunctively to a single permitted oral antidepressant.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.12-6"></a>

###### Concomitant psychotherapy

> “Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study.”
> “Psychological therapies cannot have been initiated within 30 days prior to Screening”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy.”

Source: [COMPASS Pathways support model publication release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx)

> “As of the publication date of this guidance, the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.12-7"></a>

###### Rescue medication during an administration session

> “An AE of substance induced psychotic disorder was reported for a participant who became behaviourally disinhibited during the acute drug experience.”
> “After a medical assessment, 2.5 mg oromucosal midazolam was administered.”
> “The participant recovered with no sequelae and was discharged 11 h after receiving the study intervention.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

Additional sources: [Goodwin et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37434509/)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Psilocybin on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### HEDIS Antidepressant Medication Management (AMM): definition and rationale

> “Assesses adults 18 years of age and older with a diagnosis of major depression who were newly treated with antidepressant medication and remained on their antidepressant medications.”
> “Effective Acute Phase Treatment: Adults who remained on an antidepressant medication for at least 84 days (12 weeks).”
> “Effective Continuation Phase Treatment: Adults who remained on an antidepressant medication for at least 180 days (6 months).”
> “Effective medication treatment of major depression can improve a person’s daily functioning and well-being and can reduce the risk of suicide.”

Source: [NCQA Antidepressant Medication Management](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/antidepressant-medication-management-amm/)

<a id="topic-2.1.2.13-2"></a>

###### HEDIS Antidepressant Medication Management: retirement for measurement year 2025

> “Retired for Measurement Years 2025 and 2026”
> “This measure only addresses adherence to antidepressants as a treatment for depression and does not address other recommended treatments, such as psychotherapy.”
> “Other HEDIS measures address critical gaps in depression care, including screening, follow-up, routine monitoring and improvement in outcomes.”

Source: [NCQA HEDIS measure retirement plan (2023)](https://www.ncqa.org/blog/retiring-and-replacing-hedis-measures-2024-2026/)

> “For Measurement Year 2025, NCQA added three HEDIS measures, retired four measures and made smaller changes across multiple measures.”
> “The measure does not address other guideline-recommended, non-pharmacological components of care.”
> “NCQA has a more comprehensive set of measures of depression screening, follow-up and routine monitoring, and improvement in outcomes.”

Source: [NCQA HEDIS MY 2025 changes (2024)](https://www.ncqa.org/blog/hedis-my-2025-whats-new-whats-changed-whats-retired/)

<a id="topic-2.1.2.13-3"></a>

###### HEDIS Depression Screening and Follow-Up for Adolescents and Adults (DSF-E): definition

> “The percentage of persons 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.”
> “Follow-Up on Positive Screen. The percentage of persons who received follow-up care within 30 days of a positive depression screen finding.”
> “A survey study found that major depressive disorder severity is significantly associated with increased treatment usage and costs, unemployment, disability and reduced work performance”

Source: [NCQA Depression Screening and Follow-Up](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/depression-screening-and-follow-up-for-adolescents-and-adults-dsf-e/)

<a id="topic-2.1.2.13-4"></a>

###### HEDIS Depression Remission or Response for Adolescents and Adults (DRR-E): definition and use of the PHQ-9

> “The percentage of persons 12 years of age and older with a diagnosis of depression and an elevated PHQ-9 score, who had evidence of response or remission within 120−240 days (4–8 months) of the elevated score.”
> “Depression Remission. The percentage of persons who achieved remission within 120−240 days (4–8 months) after the initial elevated PHQ-9 score.”
> “Depression Response. The percentage of persons who showed response within 120−240 days (4–8 months) after the initial elevated PHQ-9 score.”
> “The PHQ-9 is widely used by clinicians in the U.S. and commonly accepted in the behavioral health field as well.”

Source: [NCQA Depression Remission or Response](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/depression-remission-or-response-for-adolescents-and-adults-drr-e/)

<a id="topic-2.1.2.13-5"></a>

###### Electronic clinical quality measure CMS159v14, Depression Remission at Twelve Months: definition and rationale

> “MIPS Quality ID 370”
> “The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event”
> “Adolescent patients 12 to 17 years of age and adult patients 18 years of age and older who achieved remission at twelve months as demonstrated by the most recent twelve month (+/- 60 days) PHQ-9 or PHQ-9M score of less than five”
> “Results from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study showed that remission rates lowered with more treatment steps, but the overall cumulative rate was 67% (Rush et al., 2006).”

Source: [eCQI Resource Center CMS159 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0159v14)

<a id="topic-2.1.2.13-6"></a>

###### Electronic clinical quality measure CMS2v15, Screening for Depression and Follow-Up Plan: definition

> “MIPS Quality ID 134”
> “Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of or up to two days after the date of the qualifying encounter”
> “Updated numerator to include patients who have an active depression medication overlapping the date of the qualifying encounter.”

Source: [eCQI Resource Center CMS2 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0002v15)

<a id="topic-2.1.2.13-7"></a>

###### Medicaid Adult Core Set: mandatory depression screening measure for 2027

> “2027 Mandatory Adult Core Set Measures”
> “672 CMS Screening for Depression and Follow-Up Plan: Age 18 and Older (CDF-AD) Administrative or EHR”

Source: [CMS 2027 Adult Core Set](https://www.medicaid.gov/medicaid/quality-of-care/downloads/2027-adult-core-set.pdf)

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Approved pharmacotherapies for TRD in the United States

> “Currently, only two pharmacotherapies are approved for TRD in the U.S.: Spravato (esketamine), marketed by Janssen, which is an NMDA receptor antagonist; and olanzapine and fluoxetine hydrochloride capsules, which are available generically.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

###### Comparators in the ICER assessment of synthetic psilocybin

> “Data permitting, we intend to compare the agent to:”
> “Esketamine (SPRAVATO®, Janssen) / Intravenous (IV) ketamine, an anesthetic agent used off-label for TRD”
> “Repetitive Transcranial Magnetic Stimulation (rTMS)”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.1.2.14-3"></a>

###### Dosing frequency compared with esketamine: company statements

> “Today, less than 3% of these patients are accessing the only marketed and approved TRD treatment, SPRAVATO, due largely to the burden associated with the required frequency of dosing.”
> “COMP360 is poised to lead a profound shift in mental health care, moving beyond the daily antidepressants or frequent dosing required with SPRAVATO toward an option involving just a few treatments a year, fundamentally changing the way that patients living with depression are cared for.”
> “of being able to see these results within 24 hours, but then being able to maintain durability out to 12 months with just a few treatments versus the 36-54 that are required per the label with SPRAVATO.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

<a id="topic-2.1.2.14-4"></a>

###### Session monitoring time compared with esketamine: six hours and two hours

> “From a site side, this will be very consistent with what they are already doing for SPRAVATO, outside of a couple of small tweaks that would be specific to the molecule itself, like the six hours versus two hours requirement.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-5"></a>

###### Onset and durability: company statements on differentiation

> “Unlike any other approved treatment available for this patient population today, COMP360 may demonstrate effects as quickly as within one day after administration with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses.”

Source: [COMPASS Pathways rolling review and voucher release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx)

> “COMP360's profile is unique and compellingly differentiated in delivering both a rapid onset, with effects seen within 24 hours, and durability potentially out to 12 months with just a few treatments.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-6"></a>

###### TRD indication compared with psychedelics developed for major depressive disorder

> “If any of our competitors is granted an NDA for their psychedelic treatments before us and manages to obtain approval for a broader indication, such as major depressive disorder, and thus access a wider patient population, we may face more intensified competition from such potential psychedelic treatments and increased difficulties in winning market acceptance of our investigational COMP360 psilocybin treatment or any future therapeutic candidates.”
> “All of these risks are heightened because other psilocybin-based products, which may lack patent protection, may be deemed an appropriate substitute for COMP360.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “We feel very confident and very good about the TRD data versus an MDD, more generalized population, and where that may land on formulary access, most importantly, in terms of rebating and formulary position.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-7"></a>

###### Usona Institute psilocybin in major depressive disorder

> “In March 2024, Usona Institute announced the launch of its Phase 3 trial evaluating the efficacy and safety of psilocybin 25 mg as a treatment for major depressive disorder, which was expected to enroll approximately 240 adult patients, and Usona announced that it completed enrollment in its Phase 3 trial in November 2025.”
> “In April 2026, the FDA issued a National Priority Review voucher to Usona for its psilocybin as a treatment for major depressive disorder.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “Trade publication Psychedelic Alpha reported Nov. 2 that the nonprofit Usona Institute had completed an NDA for its synthetic psilocybin in major depressive disorder (MDD), a broader patient population.”
> “Usona declined to comment to the publication.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

> “Before we turn to Q&A, let me acknowledge that we are aware of the recent speculation regarding another potential filing.”
> “There has been no official statement, and we will not be providing any comments on this matter.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-8"></a>

###### Helus Pharma deuterated psilocin analog as adjunctive treatment of major depressive disorder

> “Helus Pharma is conducting a Phase 3 program for its proprietary novel serotonergic agonists (a proprietary deuterated psilocin analog) for the adjunctive treatment of major depressive disorder”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “Helus Pharma, formerly Cybin, expects topline data this quarter from APPROACH, the first of two Phase 3 trials of HLP003, a deuterated psilocin analog being tested as an add-on treatment for MDD.”
> “It is targeting an NDA in 2028.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

<a id="topic-2.1.2.14-9"></a>

###### Other late-stage psychedelic candidates in depression and TRD

> “Definium Therapeutics, formerly MindMed, has reported three positive Phase 3 readouts for DT120, an orally disintegrating tablet formulation of LSD.”
> “The company reported results from Emerge in MDD in June, followed by Voyage and Panorama in generalized anxiety disorder (GAD).”
> “Two short-acting 5-MeO-DMT candidates for TRD come next.”
> “AtaiBeckley reported starting Phase 3 activities for its intranasal BPL-003 in the second quarter.”
> “GH Research has selected doses for a global Phase 3 program of its inhaled GH001.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

> “We are aware that Supernus Pharmaceuticals, Neurocrine Biosciences, GH Research and Beckley Psytech, among others, are developing treatments for TRD or inadequate response to treatment in major depressive disorder.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.14-10"></a>

###### Polymorph patent coverage relative to other oral psilocybin products

> “As you know, it is directed to claims covering actually a number of polymorphs, and specifically the XRPD across those, and we are very confident that will withstand scrutiny from any other oral form of psilocybin.”
> “That extends to 2038 before patent term restoration, so we anticipate sort of 40, 41-ish probably.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-11"></a>

###### REMS differences expected between psilocybin and MDMA

> “I obviously can't comment on how they're thinking about the class more generally, but I would stress that there are clearly key differences between, let's say, psilocybin and MDMA, and we clearly see that should be reflected in the REMS.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: FDA draft guidance on trials in treatment-resistant depression

> “Response, partial response, and nonresponse exist on a continuum with no universally accepted”
> “efficacy in adjunctive therapy versus treatment-resistant depression (TRD) are quite different.”
> “Patients who have not responded to more than one prior”
> “antidepressant, administered at an adequate dose and duration, should be enrolled in TRD”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-2.2.1.1-2"></a>

###### Definition: EMA guideline on treatment resistance

> “Treatment resistance in depression develops in a continuum with progressively higher resistance depending on the number and nature of interventions failed.”
> “Typically, TRD trials recruit patients with demonstrated history of failure of at least two antidepressants deriving from the group(s) of products commonly used as first line treatment (of the same or a different class) prescribed at an adequate dosage for an adequate duration, with adequate affirmation of treatment adherence.”
> “However, the inclusion of patients with one failed treatment at a maximum tolerated dose and for an adequate duration can also be considered.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.1.1-3"></a>

###### Definition: regulatory definition and absence of a validated consensus definition

> “A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently exist.”
> “The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment).”
> “The EMA definition, contrary to the FDA one, explicitly states that the failed antidepressants can be from the same or different mechanistic classes.”
> “Limitations of the FDA and EMA definitions are that they do not explicitly operationalize non‐response, and do not consider psychotherapeutic interventions, regarded as first‐line treatments for mild or moderate depression by most guidelines”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.1-4"></a>

###### Definition: review of expert and trial definitions for AHRQ and CMS

> “We found that no consensus definition existed for TRD. The most common TRD definition for major depressive disorder required a minimum of two prior treatment failures and confirmation of prior adequate dose and duration.”
> “Our systematic review found that only 17% of intervention studies enrolled samples meeting the most frequently specified criteria for TRD.”

Source: [Gaynes et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31638723/)

<a id="topic-2.2.1.1-5"></a>

###### Definition: systematic review of definitions in research and clinical practice

> “In total, 155 definitions for TRD were identified in the published literature, and 48.4% of all definitions specified requirement of at least 2 treatment failures.”
> “Key informant interviews indicated the concept of TRD is rarely employed in clinical practice.”

Source: [Brown et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6591751/)

<a id="topic-2.2.1.1-6"></a>

###### Definition: Delphi consensus criteria for regulatory clinical trials

> “Based on a number of guidelines and other expert documents [22–25], in this report we adopt the definition of TRD as indicating individuals who show a reduction of less than 25% in MDD severity to at least two antidepressants, and of PRD as indicating individuals who show a reduction of between 25% and <50% in MDD severity to at least one antidepressant.”
> “We recommend (with moderate consensus, 74%) that the criteria of ‘adequate dose and duration’ is the minimal effective dosage, that is, the minimal approved dosage, administered for at least four weeks.”

Source: [Sforzini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/)

<a id="topic-2.2.1.1-7"></a>

###### Definition: CANMAT 2023 guideline

> “There is no universal consensus on a definition for TRD, but the one most frequently used is failure to respond to 2 or more antidepressant trials at a therapeutic dose and adequate duration.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.1.1-8"></a>

###### Definition: population in the ICER assessment of psilocybin

> “but a common definition is inadequate response to two different antidepressant medications despite an adequate dose and duration of treatment.”
> “adults ages 18 years and older with major depressive disorder, without psychotic features, and for whom two or more prior antidepressants prescribed at adequate dose and duration, during the current episode, have not resulted in adequate therapeutic benefit.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.1.1-9"></a>

###### Related concept: difficult-to-treat depression

> “The group proposed that DTD be defined as "depression that continues to cause significant burden despite usual treatment efforts".”
> “While DTD would seem to have clinical utility, its specificity and objectivity may be insufficient to define clinical populations for regulatory trial purposes”

Source: [McAllister-Williams et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32217227/)

> “DTD is a term proposed to extend the TRD concept and to better characterize the collaborative journey of patients and their clinicians when standard treatments have not been effective.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.1.1-10"></a>

###### Etiology: heterogeneous causal mechanisms

> “Treatment Resistant Depression (TRD) represents a heterogeneous state with likely multiple causal mechanisms.”
> “The extent to which individuals with TRD versus treatment-responsive MDD differ in etiology or pathophysiology remains mostly obscure”
> “Both childhood adversity and stress in adulthood predict increased TRD following antidepressant treatments”

Source: [Akil et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729118/)

<a id="topic-2.2.1.1-11"></a>

###### Risk factors: familial aggregation in a nationwide Taiwanese cohort

> “TRD was defined as having experienced at least 3 distinct antidepressant treatments in the current episode, each with adequate dose and duration, based on the prescribing records.”
> “First-degree relatives of individuals with TRD had lower incomes, more physical comorbidities, higher suicide mortality, and increased risk of developing TRD (aRR, 9.16; 95% CI, 7.21-11.63) and higher risk of other psychiatric disorders than matched control individuals, including schizophrenia (aRR, 2.36; 95% CI, 2.10-2.65), bipolar disorder (aRR, 3.74; 95% CI, 3.39-4.13), major depressive disorder (aRR, 3.65; 95% CI, 3.44-3.87), attention-deficit/hyperactivity disorders (aRR, 2.38; 95% CI, 2.20-2.58), autism spectrum disorder (aRR, 2.26; 95% CI, 1.86-2.74), anxiety disorder (aRR, 2.71; 95% CI, 2.59-2.84), and obsessive-compulsive disorder (aRR, 3.14; 95% CI, 2.70-3.66).”

Source: [Cheng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10993159/)

<a id="topic-2.2.1.1-12"></a>

###### Risk factors: heritability and polygenic associations in UK primary care cohorts

> “In UKB, TRD vs healthy controls and non-TRD vs healthy controls h2SNP was comparable (0.25 [SE = 0.04] and 0.19 [SE = 0.02], respectively).”
> “TRD vs non-TRD was positively associated with the PRS of attention deficit hyperactivity disorder, with lower socio-economic status, obesity, higher neuroticism and other unfavourable clinical characteristics.”

Source: [Fabbri et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8505242/)

<a id="topic-2.2.1.1-13"></a>

###### Risk factors: baseline predictors in US commercial claims

> “TRD patients at baseline were younger; 10.87% were between 18 and 19 years old versus 7.64% in the no‐TRD group, risk ratio (RR) = 1.42 (95% confidence interval [CI] 1.37–1.48).”
> “At 3.68, fatigue had the highest RR (95% CI 3.18–4.25). TRD patients had substance use disorders, psychiatric conditions, insomnia, and pain more often at baseline than non‐TRD patients.”

Source: [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/)

<a id="topic-2.2.1.1-14"></a>

###### Risk factors: sociodemographic characteristics

> “It is established that older persons more frequently fail multiple monoamine‐based antidepressant treatments, which may be taken as evidence that TRD is more common in this subpopulation”
> “It is not established whether female sex is a risk factor for TRD”
> “Socioeconomic position is a risk factor for TRD in persons receiving monoamine‐based antidepressants. For example, in the STAR*D trial, persons meeting level 2 criteria (i.e., inadequate response to two sequential antidepressant regimens) were more likely to report lower income and dependence on the public health system”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.1-15"></a>

###### Risk factors: childhood maltreatment and life stress

> “There are also studies providing evidence that a reported history of childhood emotional abuse is associated with recurrent depression, persistent depression, as well as treatment resistance to antidepressants”
> “The international Study to Predict Optimized Treatment for Depression (iSPOT‐D) reported that, amongst adults with MDD and a history of trauma between the ages of 4 and 7 years, only 15.9% achieved remission after 8 weeks of treatment with escitalopram, sertraline or venlafaxine, compared to 84.1% in individuals with no history of childhood trauma”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.1-16"></a>

###### Risk factors: illness severity, episode duration, and clinical features

> “Greater baseline severity is a highly replicated risk factor for TRD, and is indeed included in some frameworks as a variable in the hierarchical characterization of the condition.”
> “Illness duration is also highly associated with TRD, with replicated evidence indicating that the length of a depressive episode is inversely proportional to the probability of treatment response”
> “Psychotic symptoms affect approximately 20% of adults with MDD and are highly associated with TRD”
> “Results from the STAR*D trial indicate that persons presenting with anxious depression exhibit attenuated antidepressant response and are more likely to develop TRD”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

Additional sources: [Conway et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27784055/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Treatment-resistant depression

<a id="topic-2.2.1.2.1-1"></a>

###### United States commercial, Medicaid, and Medicare claims: incidence by operating definition

| Database | Cap on time for a regimen to fail | Number of cases | Incidence estimate | Incidence 95% CI |
| --- | --- | --- | --- | --- |
| CCAE | 3 months | “4,791” | “33.93” | “32.97, 34.89” |
| MDCD | 3 months | “661” | “65.71” | “60.71, 70.72” |
| MDCR | 3 months | “228” | “13.08” | “11.39, 14.78” |
| CCAE | 6 months | “7,130” | “50.49” | “49.33, 51.65” |
| MDCD | 6 months | “987” | “98.12” | “92.01, 104.24” |
| MDCR | 6 months | “320” | “18.36” | “16.36, 20.37” |
| CCAE | 24 months | “9,038” | “64.00” | “62.69, 65.32” |
| MDCD | 24 months | “1,209” | “120.20” | “113.43, 126.96” |
| MDCR | 24 months | “404” | “23.19” | “20.93, 25.45” |

Source: [Fife et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6076365/)

> “Incidence/100,000 cohort members/year.”
> “Truven MarketScan Commercial Claims and Encounters (CCAE), with approximately 35 million mainly privately insured subscribers in 2011; Truven MarketScan Medicaid (MDCD), a means-tested public insurance program with approximately 5 million subscribers in 2011, and Truven MarketScan Medicare Supplemental Beneficiaries (MCDR), a public insurance program that is not means-tested, with approximately 3 million subscribers in 2011, most of whom were aged 65 or older.”
> “we defined TRD as failure of two medications as evidenced by their replacement or supplementation by other medications, and set maximum durations (caps) for how long a medication regimen could remain in use and still be eligible to fail.”
> “TRD incidence estimates varied approximately 2-fold between the two databases (CCAE, Medicaid) that described socioeconomically different non-elderly populations; for a given cap varied 2-fold to 4-fold within each database across the other implementation choices; and if the cap was also allowed to vary, varied 6-fold or 7-fold within each database.”
> “among such studies the proportion of PTD cases that develop into TRD cases ranges from 35% in a study limited to PTD subjects with a diagnosis of MDD [9] to less than 10% in a study that included a wider range of depression diagnoses among the PTD subjects”

Source: [Fife et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6076365/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States commercial claims: progression to TRD within 1 year of newly treated depression

> “The outcome was TRD, defined as having at least three distinct antidepressants or one antidepressant and one antipsychotic within 1 year after the index date.”
> “Of 230,801 included patients, 10.4% developed TRD within 1 year.”

Source: [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/)

<a id="topic-2.2.1.2.1-3"></a>

###### United States commercial claims: treated depressive episodes meeting TRD criteria

> “Episodes of these patients in which there were at least two distinct failed regimens involving antidepressants and antipsychotics were classified as TRD.”
> “Of the treated episodes, 6.6% (N = 3,134) met the criteria for TRD. The median time to an episode becoming TRD was approximately one year.”

Source: [Kubitz et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799999/)

<a id="topic-2.2.1.2.1-4"></a>

###### United States commercial claims: treated MDD meeting TRD criteria during follow-up

> “Patients who started a third AD regimen after two regimens of appropriate duration were included in the TRD cohort.”
> “Out of 355,942 patients with MDD, 34,176 (9.6%) met the criterion for TRD.”

Source: [Li et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6771113/)

<a id="topic-2.2.1.2.1-5"></a>

###### Sweden, Stockholm region: depressive episodes progressing to TRD

> “A total of 158 169 unipolar MDD episodes (in 145 577 patients) were identified between January 1, 2012, and December 31, 2017 (64.7% women; median [IQR] age, 42 years [30-56]). Of these, 12 793 episodes (11%) fulfilled criteria for TRD.”
> “The median (IQR) time from the start of MDD episode to TRD was 552 days (294-932).”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.2.1-6"></a>

###### France, national claims sample: annual incidence and prevalence

> “Annual incidence and prevalence of TRD were estimated at 5.8 and 25.8 per 10 000 patients, respectively and at 7.8 and 37.6 per 10 000 patients, respectively in the sensitivity analysis.”

Source: [Bosco-Lévy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767421/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Treatment-resistant depression

<a id="topic-2.2.1.2.2-1"></a>

###### United States: 12-month prevalence of TRD among adults with medication-treated MDD

> “Prevalence and health care burden of TRD were estimated by synthetizing inputs across 4 similarly designed claims studies in adults covered by Medicare, Medicaid, commercial plans, and the US Veterans Health Administration (VHA).”
> “The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD.”

Source: [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States: TRD population cited in the ICER draft scope

> “Many Americans with MDD do not receive treatment at all, but among those who do, an estimated 2.8 million experience treatment-resistant depression (TRD).”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.1.2.2-3"></a>

###### United States: past-year major depressive episode among adults, NSDUH 2025

> “Among adults aged 18 or older, the percentage who had a past year MDE decreased from 8.5 percent (or 21.6 million people) in 2021 to 7.4 percent (or 19.7 million people) in 2025”
> “The percentage of adults aged 18 or older who had a past year MDE with severe impairment also decreased from 5.9 percent (or 14.9 million people) in 2021 to 5.2 percent (or 13.8 million people) in 2025”
> “Of these adults with a past year MDE, 65.9 percent (or 13.0 million people) received any of the types of mental health treatment in the past year that were described previously”
> “Among adults who had an MDE in the past year, 51.7 percent (or 10.2 million people) took prescription medication to help with their mental health”

Source: [SAMHSA (2026)](https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm)

<a id="topic-2.2.1.2.2-4"></a>

###### United States: 12-month and lifetime prevalence of DSM-5 MDD, NESARC-III

> “Of the 36 309 adult participants in NESARC-III, 12-month and lifetime prevalences of MDD were 10.4% and 20.6%, respectively.”

Source: [Hasin et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5875313/)

<a id="topic-2.2.1.2.2-5"></a>

###### United States: cumulative remission across four treatment steps, Sequenced Treatment Alternatives to Relieve Depression trial

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.1.2.2-6"></a>

###### United States: Sequenced Treatment Alternatives to Relieve Depression trial participants without remission after two treatment trials

> “In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a third of patients did not achieve remission or adequate response after two treatment trials, fulfilling requirements for treatment resistant depression (TRD).”

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

<a id="topic-2.2.1.2.2-7"></a>

###### United States: estimate based on the Sequenced Treatment Alternatives to Relieve Depression trial under FDA and EMA criteria, and range across settings

> “TRD is often stated to affect approximately 30% of persons receiving antidepressant treatment in research settings, while its prevalence in real world practice is estimated to range between 6 and 55%”
> “The FDA and EMA definitions of TRD would align with failure to level 1 and 2 treatments in the STAR*D trial.”
> “In summary, while it is often stated that TRD is affecting approximately 30% of persons receiving antidepressant treatment, a more stringent and multidimensional definition of this condition emphasizing symptomatic remission increases this estimate to about 55%.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.2.2-8"></a>

###### United States commercial claims: share of treated depression meeting a data-driven TRD rule

> “The rule transported well and states that a subject with ≥1 antipsychotic or ≥3 antidepressants in the last year has TRD. Applying this rule, 15.8% of subjects treated for depression had TRD.”

Source: [Cepeda et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5873404/)

<a id="topic-2.2.1.2.2-9"></a>

###### United Kingdom primary care: patients on repeat antidepressant prescriptions

> “Those who scored ≥14 on the BDI-II and had taken antidepressants for at least 6 weeks at an adequate dose were defined as treatment resistant.”
> “Fifty-five per cent (95% CI = 53% to 58%) (n = 1177) met the study’s definition of TRD, of whom 67% had taken their antidepressants for more than 12 months.”

Source: [Thomas et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3839394/)

<a id="topic-2.2.1.2.2-10"></a>

###### Canada primary care: consecutive patients with MDD

> “Using failure to respond to at least 2 antidepressants (ADs) from different classes as the definition of TRD, the overall prevalence was 21.7%.”
> “The prevalence across provinces varied (P < 0.001), with British Columbia having the highest rate (28.7%) and Alberta the lowest rate (12.8%).”

Source: [Rizvi et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086317/)

<a id="topic-2.2.1.2.2-11"></a>

###### United Kingdom primary care records: UK Biobank and EXCEED

> “Among individuals with MDD with at least one record of antidepressant prescription, the prevalence of TRD was 13.49% (n = 159) and 13.2% (n = 2430) in EXCEED and UKB, respectively”

Source: [Fabbri et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8505242/)

<a id="topic-2.2.1.2.2-12"></a>

###### Scotland and UK Biobank health records: proportion by definition

> “The reference TRD definition included 10% of depression cases in the routine data collection, but substantially fewer cases (4%) in consented cohorts.”

Source: [Iveson et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13245096/)

<a id="topic-2.2.1.2.2-13"></a>

###### Sweden, national registers: antidepressant initiators classified with TRD

> “Patients with at least two additional treatment trials during the same depressive episode were classified as having TRD.”
> “In total 15,013 patients (13%) were classified with TRD.”

Source: [Reutfors et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29966932/)

<a id="topic-2.2.1.2.2-14"></a>

###### France, national claims sample: annual prevalence

> “Annual incidence and prevalence of TRD were estimated at 5.8 and 25.8 per 10 000 patients, respectively and at 7.8 and 37.6 per 10 000 patients, respectively in the sensitivity analysis.”

Source: [Bosco-Lévy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767421/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Course: relapse and recovery in medium- to long-term outcome studies

> “We identified nine outcome studies with a total of 1279 participants and follow-up duration of between 1 and 10 years. In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission. For those with a more protracted illness, the probability of recovery within 10 years was about 40%. TRD was also associated with poorer quality of life and increased mortality.”

Source: [Fekadu et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19007996/)

<a id="topic-2.2.1.3-2"></a>

###### Course: relapse by number of treatment steps, Sequenced Treatment Alternatives to Relieve Depression trial

> “Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”
> “When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.1.3-3"></a>

###### Course: two-year outcomes under treatment as usual

> “The 12- and 24-month IDS-SR-30 response rates were 11.6% (13/112) and 18.4% (19/103), respectively. Of the 13 responders at 12 months, only 5 were responders at 24 months. The 12- and 24-month IDS-SR-30 remission rates were 3.6% (4/112) and 7.8% (8/103), respectively. Only 1 of the 4 12-month remitters was also a remitter at 24 months.”
> “Despite the wide range of treatment options available for depression, the response rates, remission rates, and quality-of-life results in this study show that most patients with a substantial degree of treatment resistance continue to have significant symptomatology and functional disability when receiving TAU.”

Source: [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/)

<a id="topic-2.2.1.3-4"></a>

###### Course: episode duration in US commercial claims

> “The mean duration of a TRD episode was 1,004 days (vs. 452 days for a non-TRD episode).”

Source: [Kubitz et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799999/)

<a id="topic-2.2.1.3-5"></a>

###### Course: time between treatment trials in the Stockholm cohort

> “Median time from start of the first antidepressant treatment to start of the second, and from start of the second antidepressant treatment to start of the third, was 165 and 197 days, respectively.”
> “Episode duration was longer in the TRD group than in the non-TRD group”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.3-6"></a>

###### All-cause mortality: US commercial claims

> “TRD was associated with a significantly higher mortality compared with non-TRD MDD (adjusted HR: 1.29; 95% CI 1.22–1.38; p < 0.0001). Survival time was significantly shorter in the TRD cohort compared with the non-TRD MDD cohort (p < 0.0001).”

Source: [Li et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6771113/)

<a id="topic-2.2.1.3-7"></a>

###### All-cause and external-cause mortality: Swedish national registers

> “Adjusted HR for all-cause mortality was 1.35 (95% CI 1.21-1.50). Mortality from external causes (including suicides and accidents) was markedly higher in TRD patients than in other depressed patients (HR 1.97; 1.69-2.29), while mortality from non-external causes was similar. The adjusted EMRR was 1.52 (1.31-1.76), highest among patients 18-29 years old (EMRR 2.03; 1.31-1.76) and patients without somatic comorbidity (EMRR 1.99; 1.63-2.43).”

Source: [Reutfors et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29966932/)

<a id="topic-2.2.1.3-8"></a>

###### All-cause mortality: Stockholm MDD cohort

> “The all-cause mortality rate for patients with MDD with TRD episodes was 10.7/1000 person-years at risk, compared with 8.7/1000 person-years at risk for patients with MDD without TRD episodes (hazard ratio, 1.23; 95% CI, 1.07-1.41).”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.3-9"></a>

###### Excess deaths: Swedish national registers

> “Compared with the mortality risk of other depressed patients, patients with TRD experienced excess deaths in most age and comorbidity categories in the range of 7–16 deaths per 1000 patients during 5 years. Highest numbers for all-cause excess deaths were found among patients 18–29 years old with CCI 1, where 16 [95% confidence interval 5–28] of the expected 37 [25–48] deaths per 1000 patients were excess deaths. The majority of the excess deaths were due to external causes.”

Source: [Brenner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8047832/)

<a id="topic-2.2.1.3-10"></a>

###### Suicide mortality: US commercial and Medicare claims linked to the National Death Index

> “For the 139,753 TRD, 85,602 MDD+SI/SA, and 572,098 MDD alone cohort patients, mean age ranged from 55 to 59 years and the majority were female.”
> “Suicide‐mortality rates in the three cohorts were 0.14/100 person‐years for TRD, 0.27/100 person‐years for MDD+SI/SA, and 0.04/100 person‐years for MDD alone.”

Source: [Kern et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454258/)

> “Patients with TRD have a greater than 3-fold risk of death by suicide than patients with non-TRD MDD.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.1.3-11"></a>

###### Suicide and suicide attempts: meta-analysis of TRD samples after treatment initiation

> “Thirty percent of patients with treatment-resistant depression (TRD) attempt suicide at least once during their lifetime.”
> “The overall incidence of completed suicides was 0.47 per 100 patient years (95% CI: 0.22-1.00), and of attempted suicides 4.66 per 100 patient years (95% CI: 3.53-6.23). No differences were found in incidences following DBS, VNS or ECT.”

Source: [Bergfeld et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29665520/)

<a id="topic-2.2.1.3-12"></a>

###### Suicide and suicide attempts: risk factors in Swedish national registers

> “In all, 178 patients died by suicide and 1,242 experienced a suicide attempt during follow-up.”
> “History of suicide attempts, especially if <1 year after the attempt, was a significant independent risk factor for suicide (adjusted odds ratio [aOR], 8.9; 95% confidence interval [CI], 5.1-15.7) as were 10 to 12 years of education compared to lower education (aOR, 1.69; 95% CI, 1.02-2.81).”

Source: [Reutfors et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/31774374/)

<a id="topic-2.2.1.3-13"></a>

###### Intentional self-harm: Stockholm MDD cohort

> “Intentional self-harm was more than 4 times more common in TRD episodes.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Overview: limited distinction from treatment-responsive depression

> “TRD patients exhibit the same diversity of symptoms, course, history and co-occurring conditions as for treatment-responsive MDD.”
> “It must be emphasized that the following mechanisms and etiological processes have not yet been compared sufficiently between TRD versus treatment-responsive MDD. Establishing areas of similarities and differences between the two is a high priority of current research.”

Source: [Akil et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729118/)

<a id="topic-2.2.1.4-2"></a>

###### Stress response: hypothalamic-pituitary-adrenal axis

> “Studies of the neurobiology of depression, including TRD, focus largely on the association between stress and depression, with the hope that an understanding of the biological pathways that link stress to depression would inform on the pathophysiology of the disorder.”

Source: [Akil et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729118/)

> “Altered functioning of the hypothalamic-pituitary-adrenal (HPA) axis has been demonstrated in patients with treatment-resistant depression, although studies have often conflated patients with unipolar and bipolar depression.”
> “Patients with TRUD had higher total cortisol production in the morning hours compared to controls (AUCg, p = 0.01), while they did not differ in terms of the awakening response (AUCi, p = 0.28).”

Source: [Markopoulou et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8076168/)

<a id="topic-2.2.1.4-3"></a>

###### Inflammation: peripheral C-reactive protein

> “Compared with healthy volunteers, BMI-corrected CRP was significantly elevated in the treatment-resistant group (P = 0.007; Cohen's d = 0.47); but not significantly so in the treatment-responsive (d = 0.29) and untreated (d = 0.18) groups.”
> “CRP was elevated in patients with MDD, and more so in treatment-resistant patients. Other phenotypes associated with elevated CRP included childhood adversity and specific depressive and anxious symptoms.”

Source: [Chamberlain et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6124647/)

> “Immune-related mechanisms are increasingly recognised as important in the pathophysiology of depression, particularly treatment-resistant depression (TRD).”

Source: [Strawbridge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244173/)

<a id="topic-2.2.1.4-4"></a>

###### Glutamate signaling and glial cells

> “Although excessive glutamatergic neurotransmission and consequent excitotoxicity were considered a major cause of TRD, recent evidence suggests that the extrasynaptic glutamatergic receptor signal pathway mainly contributes to the detrimental effects of TRD.”
> “Glial cells such as microglia and astrocytes, early life adversity, and glucocorticoid receptor dysfunction participate in complex cross-talk.”
> “Excessive microglial activation and the inflammatory process cause astrocyte glutamatergic dysfunction, which in turn activates microglial function.”

Source: [Kim and Na (2016)](https://pubmed.ncbi.nlm.nih.gov/27046518/)

<a id="topic-2.2.1.4-5"></a>

###### Brain networks: neuroimaging differences between TRD and non-TRD

> “Our main findings are that patients with TRD show 1) reduced functional connectivity (FC) within the default mode network (DMN), 2) reduced FC between components of the DMN and other brain areas, and 3) hyperactivity of DMN regions. In addition, aberrant activity and FC in the occipital lobe may play a role in TRD.”
> “The main limitations of most studies were related to inherent confounding factors for comparing TRD with non-TRD, such as differences in disease chronicity/severity and medication history.”

Source: [Runia et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34890601/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic criteria for major depression

> “The detection of MDD requires the presence of depressed mood or loss of interest and pleasure in activities accompanied by at least two (ICD-10) or five (DSM-5) symptoms of depression. These core symptoms may vary from patient to patient, however, they are typically seen for much of the day, almost always every day for at least two weeks and are associated with relevant psychological distress and considerable impairment in social, occupational, or other important areas of functioning.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.1.5-2"></a>

###### Diagnostic assessment: structured interview and treatment history instruments

> “At a minimum, assessment to define TRD should include a structured clinical interview for the diagnosis of MDD, such as the Structured Clinical Interview for DSM (SCID) [53, 54] and the Mini-International Neuropsychiatric Interview (MINI) [55], together with a scale to assess the patient’s antidepressant history, such as the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) [56], and the Antidepressant Treatment History Form (ATHF) [57]. A more structured method is to use staging models [6, 58], such as the Thase and Rush method [59], the Massachusetts General Hospital Staging model (MGH-s) [22], and the more recent Maudsley Staging Model (MSM) [60], which also allows the assessment of previous antidepressant treatment failure, using the Maudsley Treatment Inventory (MTI) [10].”
> “Among the experts, there was a substantial agreement that staging models are the preferred instrument to define TRD/PRD and assess the level of treatment-resistance, even if many experts recognize the validity of the ATRQ, often accepted in regulatory clinical trials.”

Source: [Sforzini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/)

<a id="topic-2.2.1.5-3"></a>

###### Confirming treatment resistance: retrospective assessment and screening for bipolarity

> “Retrospective assessment of treatment failure should be primarily based on medical records of previous treatment if such records can be obtained, and not on the patient’s recollection of symptom improvement, which may be biased.”
> “Patients should be carefully screened for previous episodes of mania, hypomania or sub-threshold bipolarity and this would increase the accuracy of population selection”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.1.5-4"></a>

###### Confirming treatment resistance: excluding pseudo-resistance

> “Reviewed herein are the most common modifiable contributors to pseudo‐resistance, including inaccuracy of the MDD diagnosis, inadequacy of current and past treatment trials, inaccurate assessment of response, and individual differences in the metabolism of antidepressants”
> “Inaccuracy of the MDD diagnosis is a common reason for pseudo‐resistance. It is estimated that approximately half of individuals with MDD are not correctly diagnosed”
> “Furthermore, it is reported that the transition from a diagnosis of MDD to one of bipolar disorder occurs at a rate of approximately 1‐3% per year, indicating that diagnostic assessment must be reconsidered in all TRD presentations”
> “The adequate duration of an antidepressant trial is generally considered to be 4‐6 weeks at optimal dosing, although 60% of persons who achieved remission in the STAR*D trial with level 1 treatment did so after week 6 of treatment, indicating that a subpopulation of adults with MDD may require longer treatment trials”
> “Using this definition, about 30‐50% of persons prescribed with antidepressants are non‐adherent in acute phase treatment”
> “Although pharmacogenetic testing cannot be recommended as a routine assessment in TRD, some preliminary evidence does suggest that, in select circumstances, it may be warranted.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

> “Furthermore, determining the adequacy of prior treatment is essential since substantial evidence indicates that large numbers of depressed patients are undertreated, resulting in prolonged episodes and the appearance of "pseudoresistance."”

Source: [Sackeim (2001)](https://pubmed.ncbi.nlm.nih.gov/11480879/)

<a id="topic-2.2.1.5-5"></a>

###### Guideline recommendation: reassessment after poor response

> “The first steps in the assessment of poor response involve re-evaluating the diagnosis (e.g., a missed diagnosis of bipolar disorder), comorbidities, and adherence to treatment. In addition to clinical reassessment, laboratory investigations should be considered to rule out potential medical factors that can contribute to persistent symptoms and that require additional interventions.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “A diagnostic re-evaluation is essential to the proper management of these patients. In particular, the potential role of several contributing factors, such as medical and psychiatric comorbidity, needs to be taken into account.”

Source: [Fava (2003)](https://pubmed.ncbi.nlm.nih.gov/12706951/)

<a id="topic-2.2.1.5-6"></a>

###### Staging models: Thase and Rush model

> “In this paper, alternate antidepressant strategies are reviewed within the context of a five-stage strategy, ranging from lesser to greater degrees of treatment resistance. The overall strategy recommended progresses from simpler (i.e., an alternate monotherapy) to more complex strategies (i.e., combination or augmentation regimens), with the nonselective monoamine oxidase inhibitors (+/- lithium salts) and electroconvulsive therapy typically reserved for treatment of Stages III and IV of resistance, respectively.”

Source: [Thase and Rush (1997)](https://pubmed.ncbi.nlm.nih.gov/9402916/)

> “Stage I is defined by failure of at least one adequate trial of one major class of antidepressants; stage II by failure of at least two adequate trials of at least two distinctly different classes of antidepressants; stage III by stage II resistance plus failure of an adequate trial of a tricyclic antidepressant (TCA); stage IV by stage III resistance plus failure of an adequate trial of a monoamine oxidase inhibitor (MAOI); and stage V by stage IV resistance plus failure of a course of bilateral electroconvulsive therapy (ECT).”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.5-7"></a>

###### Staging models: Maudsley Staging Method

> “We present a points-based staging model incorporating 3 factors: treatment, severity of illness, and duration of presenting episode. In this model, the rating of symptom severity ranges from subsyndromal depression (score 1) to severe syndromal depression with psychosis (score 5). Antidepressant treatment is rated on a 5-point subscale based on number of medications used, while duration of the presenting episode is rated on a 3-point subscale. The overall level of resistance estimated using this model varies from minimal resistance (score of 3) to severe resistance (score of 15).”

Source: [Fekadu et al. (2009b)](https://pubmed.ncbi.nlm.nih.gov/19192471/)

> “The core dimension of the MSM, treatment failure, may be assessed using the Maudsley Treatment Inventory (MTI), a new method developed for the purposes of completing the MSM. The MTI consists of a relatively comprehensive list of medications with options for rating doses and provisions treatment for multiple episodes. The second dimension, severity of symptoms, may be assessed using simple instruments such as the Clinical Global Impression, the Psychiatric Status Rating or checklist from a standard diagnostic checklist. The standardisation also provides a simple rating scale for scoring the third dimension, duration of depressive episode.”

Source: [Fekadu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5896127/)

<a id="topic-2.2.1.5-8"></a>

###### Staging models: Massachusetts General Hospital model

> “One point is assigned for non‐response to each adequate trial of a marketed antidepressant (duration of at least six weeks and adequate dosage). Half a point is assigned for each trial based on optimization of dose, optimization of duration, or an augmentation/combination strategy. Three points are assigned for non‐ response to ECT.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.5-9"></a>

###### Staging models: systematic review of five models

> “From 950 retrieved articles five staging models were found; the Antidepressant Treatment History Form, Thase and Rush Model, European Staging Model, Massachusetts General Hospital Staging model and the Maudsley Staging Model (MSM). Six studies investigated the predictive utility (of four models). We observed an evolution from single antidepressant adequacy ratings, towards a multidimensional and more continuous scored staging model which also introduced TRD characteristics (severity and duration). The operationalization criteria improved; the scoring of different treatment strategies (between/within class switching and augmentation/combination) changed according to the existing evidence. Over time, efforts to validate models improved. The predictive utility was assessed best for the MSM.”
> “Few staging models existed; their reliability was hardly assessed.”

Source: [Ruhé et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/21435727/)

<a id="topic-2.2.1.5-10"></a>

###### Rating scales: instruments accepted for trials

> “Acceptable scales to determine symptomatic improvement include the Hamilton Rating Scale of Depression (HDRS), preferably the 17-item scale, and the Montgomery-Asberg Depression Rating Scale (MADRS), however other validated scales might be acceptable as well.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

> “We recommend (with moderate consensus) that the clinician administered MADRS10 is the preferred outcome instrument to assess treatment response (and remission) (85%), together with patient-reported QIDS-SR (81%).”

Source: [Sforzini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/)

<a id="topic-2.2.1.5-11"></a>

###### Rating scales: Montgomery-Åsberg Depression Rating Scale development

> “Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change.”
> “Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-2.2.1.5-12"></a>

###### Rating scales: response, nonresponse, and remission thresholds

> “Early improvement is often defined with a symptom scale as a reduction in score of 20% or greater from baseline (within 2 to 4 weeks after treatment initiation), whereas response is defined as 50% or greater improvement from baseline. Symptom remission is indicated by a specific threshold score for each scale, e.g., a score of 7 or less on the Hamilton Depression Rating Scale (HAM-D), 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), and 4 or less on the PHQ-9.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “An exception is the GSRD staging method 14 , which explicitly defines treatment non‐response as a reduction of less than 50% in the total score on the HAM‐D or the MADRS.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%. If a state of almost complete absence of symptoms were required for a definition of remission, a MADRS total score would be <8, because such scores corresponded to a CGI-S score of 2 ('borderline mentally ill').”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

Additional sources: [Hamilton (1960)](https://pmc.ncbi.nlm.nih.gov/articles/PMC495331/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Mood symptoms: depressed mood and loss of interest or pleasure

> “NSDUH respondents were classified as having had a major depressive episode (MDE) in the past 12 months if (1) they had at least one period of 2 weeks or longer in the past year when, for most of the day nearly every day, they felt depressed or lost interest or pleasure in daily activities; and (2) they also had problems with sleeping, eating, energy, concentration, self‐worth, or having recurrent thoughts of death or recurrent suicidal ideation.”

Source: [SAMHSA (2026)](https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm)

<a id="topic-2.2.1.6-2"></a>

###### Mood symptoms: anhedonia

> “Anhedonia is a core component of depression endorsed by 35‐75% of patients, and may be a risk factor for TRD in persons whose treatment history is delimited to SSRIs”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.6-3"></a>

###### Symptom clusters: mood, insomnia, somatic, and anxiety symptoms in TRD

> “This work found that patients with TRD referred for rTMS experience four distinct symptom clusters - mood, insomnia, somatic and anxiety symptoms - and that these clusters respond differently to rTMS.”

Source: [Kaster et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9722479/)

<a id="topic-2.2.1.6-4"></a>

###### Somatic and neurovegetative symptoms: fatigue, insomnia, and pain before TRD onset

> “Ten percent of subjects newly diagnosed and treated for depression developed TRD within a year. They were younger and suffered more frequently from fatigue, substance use disorders, anxiety, psychiatric conditions, insomnia, and pain than non‐TRD patients.”

Source: [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/)

<a id="topic-2.2.1.6-5"></a>

###### Cognitive symptoms: deficits in multiple cognitive domains

> “Cognitive dysfunction is considered a core feature in the psychopathology of MDD during both the acute phase and the residual period and represents one of the symptoms for which a clinical need has been identified. Sufficient evidence exists indicating that patients suffering from MDD exhibit deficits in multiple domains of cognitive function, including learning and memory (verbal and nonverbal), attention, psychomotor speed, executive function, emotional processing and social cognition. Cognitive dysfunction may persist as residual symptom, despite resolution of the depressive symptoms in the acute phase.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

> “Cognitive deficits in MDD are prevalent, persistent, and often progressively increase as a function of illness severity and duration; they are associated with attenuated response to select antidepressants, and may represent a risk factor for TRD”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.6-6"></a>

###### Anxiety symptoms: anxious depression and comorbid anxiety disorders

> “Anxiety symptoms are frequently reported in TRD populations, and their presence in MDD is associated with a more severe illness presentation, lower probability of remission, comorbidities and suicidality”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

> “At baseline, anxiety disorders were present in 53.92%, 44.11%, and 21.72% of patients with TRD, MDD+SI/SA, and MDD alone, respectively.”

Source: [Kern et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454258/)

> “Two hundred fifty-three patients, who had at least one post-baseline Montgomery-Asberg Depression Rating Scale and Hamilton Depression Rating Scale score were included in the analysis. Of them, 182 subjects presented anxious and 71 nonanxious depression.”

Source: [Chaikali et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42127355/)

> “The anxiety symptom cluster was significantly less responsive to treatment than other symptom clusters (t(6001) = -8.02, p < 0.001).”

Source: [Kaster et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9722479/)

<a id="topic-2.2.1.6-7"></a>

###### Psychotic and mixed features

> “Mixed features are reported to be present in approximately 25% of persons with MDD and are associated with attenuated antidepressant response, although it remains to be determined whether they are a risk factor specifically for TRD”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.6-8"></a>

###### Suicidal ideation and hopelessness

> “More than half of patients reported thoughts or wishes of death to self and significant hopelessness.”
> “Patients with TRD are more likely than not to report prominent suicidal ideation and hopelessness.”

Source: [Papakostas et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12891091/)

<a id="topic-2.2.1.6-9"></a>

###### Functional impairment: work, social functioning, and quality of life

> “During follow-up, TRD patients had lower health-related quality of life (HRQOL) scores on mental (30 vs 45.7) and physical components (47.7 vs 48.9) of the SF12, and lower Q-LES-Q scores (43.6 vs 63.7), greater functional and work impairments and productivity loss vs non-TRD patients (all p < 0.05).”

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

<a id="topic-2.2.1.6-10"></a>

###### Residual symptoms after treatment

> “Nearly 70% of patients with MDD experience residual symptoms with first line standard of care. These may include anxiety, impaired cognition, fatigue and sleep disturbance.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

> “This was highlighted in the STAR*D trial, in which it was observed that only 10% of persons “in remission” were fully asymptomatic”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Physical comorbidity: incident cardiovascular and metabolic disease

> “It is well established that TRD populations have a higher rate of psychiatric and physical comorbidities as compared to non‐TRD populations 143 . In addition, TRD is a risk factor for incident physical comorbidities, such as cardiovascular disease, type 2 diabetes mellitus, osteoporosis, and metabolic syndrome”
> “For example, it is established that MDD is a risk factor for cardiovascular disease, obesity and type 2 diabetes mellitus, and this is especially apparent in individuals with more severe and/or persistent depressive syndromes, which are over‐represented in TRD populations”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.7-2"></a>

###### Cardiovascular events: major adverse cardiovascular events in Swedish registers

> “We identified 143,731 patients with depression, including 23,335 with TRD and 45,217 with severe depression. Patients with depression had a higher hazard of MACE vs comparators (aHR 1.50, 95%CI 1.40-1.62). Hazards of MACE were overall similar in patients with TRD vs comparators (aHR 1.06, 95%CI 0.93-1.22) and severe depression vs comparators (aHR 1.04, 95%CI 0.96-1.13). Analyzing separate outcomes, patients with TRD had a higher hazard of cardiovascular death (aHR 1.32, 95 %CI 1.03-1.69).”
> “Patients with TRD or severe depression are not at additional overall risk of MACE compared to other depressed patients. However, an additional risk may exist in younger patients with severe depression and specifically of cardiovascular death in patients with TRD.”

Source: [Nygren et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381860/)

<a id="topic-2.2.1.7-3"></a>

###### Psychiatric comorbidity: Stockholm MDD cohort

> “In patients with TRD, we observed a gradual increase in the prevalence of all psychiatric comorbid diagnoses during the year preceding the TRD index date, most pronounced for anxiety and stress (60% and 36%, respectively)”
> “Table 1 also shows an increased prevalence for sleep disorders, substance abuse, personality disorders, and intentional self-harm in patients with TRD.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.7-4"></a>

###### Comorbidity, obesity, and disability: Canadian primary care

> “Higher rates of disability and comorbidity (axes I to III) were associated with treatment resistance. Obesity and being overweight were also associated with treatment resistance.”

Source: [Rizvi et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086317/)

<a id="topic-2.2.1.7-5"></a>

###### Work disability: lost workdays in the Stockholm MDD cohort

> “Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.7-6"></a>

###### Quality of life and functional disability under usual care

> “The SF-36 indicated globally poor quality of life in this sample.”

Source: [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Treatment-resistant depression

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Quality of life, functioning, and work productivity in TRD versus non-TRD MDD: Sequenced Treatment Alternatives to Relieve Depression trial secondary analysis

> “A total of 2467 (TRD: 377; non-TRD: 2090) patients were studied.”
> “During follow-up, TRD patients had lower health-related quality of life (HRQOL) scores on mental (30 vs 45.7) and physical components (47.7 vs 48.9) of the SF12, and lower Q-LES-Q scores (43.6 vs 63.7), greater functional and work impairments and productivity loss vs non-TRD patients (all p < 0.05).”

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

| Endpoint | TRD | Non-TRD | P value |
| --- | --- | --- | --- |
| SF-12 mental component score | “30.0” | “45.7” | “<.0001” |
| SF-12 physical component score | “47.7” | “48.9” | “0.0126” |
| Q-LES-Q general activities index | “43.6” | “63.7” | “<.0001” |
| Work and Social Adjustment Scale score | “23.4” | “11.3” | “<.0001” |
| WPAI activity impairment, % | “54.5” | “30.5” | “<.0001” |
| WPAI percent hours missed | “19.6” | “9.5” | “<.0001” |
| WPAI overall work impairment, % | “52.9” | “24.9” | “<.0001” |

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

<a id="topic-2.2.1.8.1-2"></a>

###### EQ-5D-5L utility and work productivity in TRD versus non-TRD MDD: United Kingdom non-interventional study

> “148 patients with clinician-verified symptomatic (non-treatment-resistant) MDD (Patients-MDD; n = 61) or TRD (Patients-TRD; n = 87) were recruited from ten clinical sites.”
> “However, HRQoL was significantly poorer for Patients-TRD compared with Patients-MDD, both in the overall cohort (median EQ-5D-5 L utility 0.606/0.721, respectively [p = 0.021]; WHOQOL-BREF overall score 55.2/58.8 [p = 0.024]) and in patients with a PHQ-9 score ≥15 (median EQ-5D-5 L utility 0.415/0.705, respectively [p<0.001]).”
> “Although a numerically lower proportion of Patients-TRD were employed (45% vs 57% of Patients-MDD; p = 0.204), employed Patients-MDD reported significantly higher absenteeism and work productivity loss.”

Source: [Rathod et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34965398/)

<a id="topic-2.2.1.8.1-3"></a>

###### EQ-5D-5L, SF-12v2, and work and activity impairment versus non-TRD depression and the general population: five European countries

> “A total 52,060 survey respondents were examined, of which 2686 and 622 were considered to have non-treatment resistant and treatment-resistant depression, respectively.”
> “Relative to the general population, nTRD and TRD respondents reported significant decrements in health-related quality of life, including lower adjusted mental (− 12.1 vs. -18.1) and physical (− 2.5 vs. -5.4) component scores of the SF-12v2 and increased adjusted relative risk for work (2.2 vs. 2.7) and activity (1.9 vs. 2.5) impairment (all p < 0.001).”
> “After adjusting for demographics and health characteristics, TRD and nTRD groups had poorer health status as assessed by the EQ-5D-5 L (− 0.329 and − 0.173, respectively, both p < 0.001) and EQ-VAS (− 27.440 and − 16.724, respectively, both p < 0.001) compared to the general population.”

Source: [Jaffe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6686569/)

<a id="topic-2.2.1.8.1-4"></a>

###### EQ-5D-5L, employment, and work productivity at treatment initiation: European real-world TRD cohort

> “Overall, 411 eligible patients were enrolled across seven European countries.”
> “Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed.”
> “At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively.”
> “The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%).”

Source: [Heerlein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33545659/)

<a id="topic-2.2.1.8.1-5"></a>

###### Proportion reporting problems on each EQ-5D-5L dimension at baseline: esketamine phase 3 trial population

> “The full analysis set included 223 patients (ESK + AD: 114; AD + PBO: 109; mean [SD] age: 45.7 [11.89]).”

Source: [Jamieson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10169482/)

| EQ-5D-5L dimension | Esketamine plus antidepressant group at baseline, % | Antidepressant plus placebo group at baseline, % |
| --- | --- | --- |
| Mobility | “28.1” | “34.9” |
| Self-care | “53.5” | “53.2” |
| Usual activities | “94.8” | “92.7” |
| Pain/Discomfort | “68.5” | “74.3” |
| Anxiety/Depression | “98.3” | “99.9” |

Source: [Jamieson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10169482/)

<a id="topic-2.2.1.8.1-6"></a>

###### Quality-of-life decrement versus remission or response: systematic review of United States data, 1996 to 2013

> “Sixty-two articles were included (N=59,462 patients).”
> “Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response.”

Source: [Mrazek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24789696/)

<a id="topic-2.2.1.8.1-7"></a>

###### Quality of life across increasing levels of non-response: systematic review

> “Likewise, the 19 studies studying HRQoL burden found that increasing levels of TRD/non-response correlated with reduced patient HRQoL and health status.”
> “A consistent trend was observed such that medical costs increased and patient HRQoL and health status decreased by increasing level of TRD/non-response within an MDD episode.”

Source: [Johnston et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30195173/)

<a id="topic-2.2.1.8.1-8"></a>

###### Health state utilities by depression severity used in a United States cost-effectiveness model of esketamine

> “Patient EQ-5D health index scores were measured at baseline and stratified according to baseline PHQ-9 levels of mild (< 10), moderate (11 to 15), moderately-severe (16 to 20), and severe depression (> 20).”
> “Characteristics of patients in this study were similar to those in the TRANSFORM trials, with an average number of 3.6 treatment failures and PHQ-9 score of 18.3.”

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

| Health state | Base-case utility |
| --- | --- |
| No depression, gender adjusted | “0.86” |
| Mild to moderate depression | “0.68” |
| Severe depression | “0.50” |

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### National annual burden of TRD within medication-treated MDD in the United States

> “The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD.”
> “The total annual burden of medication-treated MDD among the US population was $92.7 billion, with $43.8 billion (47.2%) attributable to TRD.”
> “The share of TRD was 56.6% ($25.8 billion) of the health care burden, 47.7% ($8.7 billion) of the unemployment burden, and 32.2% ($9.3 billion) of the productivity burden of medication-treated MDD.”

Source: [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/)

<a id="topic-2.2.1.8.2-2"></a>

###### Incremental societal economic burden of MDD in the United States in 2019

> “In 2019, the number of adults with MDD in the USA was estimated at 19.8 million (62.7% female; 32.9% severe MDD), and the incremental societal economic burden of MDD was estimated at $333.7 billion ($382.4 billion in 2023 US dollars), or $16,854 per adult with MDD.”
> “The primary cost drivers were healthcare costs ($127.3 billion; 38.1%), household-related costs ($80.1 billion; 24.0%), presenteeism ($43.3 billion; 13.0%), and absenteeism ($38.4 billion; 11.5%).”
> “In the simulated scenario, a hypothetical novel therapy with a 50.0% early response rate was associated with a 7.7% reduction in the economic burden of MDD relative to standard of care over 12 months.”

Source: [Greenberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499687/)

<a id="topic-2.2.1.8.2-3"></a>

###### Commercially insured adults: health care costs, work loss, and employment status change

> “TRD patients (N = 6,411) had more HRU than either matched control cohort, translating into higher per patient per year (PPPY) health care costs: $6,709 and $9,917 more than non-TRD MDD and non-MDD patients, respectively (P < .001 for both).”
> “TRD patients with work loss data (N = 1,908) had 35.8 work loss days PPPY (1.7 and 6.2 times the work loss rate in non-TRD MDD and non-MDD patients, respectively).”
> “Work loss-related costs in TRD patients were $1,811 higher than non-TRD MDD and $3,460 higher than in non-MDD patients (P < .001).”
> “TRD patients had 1.3-1.4 times the rate of employment status change versus control cohorts (all P < .05).”

Source: [Amos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29474009/)

<a id="topic-2.2.1.8.2-4"></a>

###### Commercially insured adults with physical conditions: resource use, health care costs, and work loss

> “A total of 2,317 patients with TRD (mean age, 47.6 years; 63.1%, female; mean follow-up, 19.7 months) had ≥ 1 co-occurring key physical condition (cardiovascular, 52.5%; metabolic, 48.2%; respiratory, 16.4%; and cancer, 9.5%).”
> “Relative to non-TRD MDD and non-MDD cohorts, respectively, patients with TRD had 46% and 235% more inpatient admissions, 28% and 128% more emergency department visits, and 53% and 155% more outpatient visits (all P < 0.05).”
> “Health care costs were $22,541 in the TRD cohort, $17,450 in the non-TRD MDD cohort, and $10,047 in the non-MDD cohort, yielding cost differences of $5,091 (vs. non-TRD MDD) and $12,494 (vs. non-MDD; all P < 0.01).”
> “In patients with work loss data available (n = 278/cohort), those with TRD had 2.0 and 2.9 times more work loss as well as $8,676 and $10,323 higher work loss costs relative to those with non-TRD MDD and without MDD, respectively (all P < 0.001).”

Source: [Zhdanava et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391320/)

<a id="topic-2.2.1.8.2-5"></a>

###### Commercially insured employees: direct and indirect costs over 2 years

> “Employees who initiated a third antidepressant following two antidepressant treatments of adequate dose and duration or who met published TRD criteria were classified as TRD likely (N = 2312).”
> “Average direct 2-year costs were significantly higher for TRD-likely employees ($22,784) compared with MDD controls ($11,733), p < 0.0001.”
> “Average indirect costs were also higher among TRD-likely employees ($12,765) compared with MDD controls ($6885), p < 0.0001.”

Source: [Ivanova et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20825269/)

<a id="topic-2.2.1.8.2-6"></a>

###### Commercially insured adults: episode duration and total costs of TRD episodes

> “Of all episodes, 7% were TRD, with a mean duration of 571 (285) days vs. 200 (198) days for non-TRD MDD episodes.”
> “Mean total all-cause costs were $19,626 ($44,160) for TRD and $7440 ($25,150) for non-TRD MDD episodes.”

Source: [Cai et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31540559/)

<a id="topic-2.2.1.8.2-7"></a>

###### Medicare beneficiaries: resource use and health care costs

> “Of these, 3,224 (10.9%) met the study definition of TRD.”
> “During the observation period, the total all-cause PPPY healthcare costs were $25,059 in the TRD cohort, $19,945 in the non-TRD MDD cohort, and $14,410 in the non-MDD cohort (all P<0.001; Fig 3 and Table 2).”
> “The TRD cohort had significantly higher adjusted PPPY all-cause healthcare costs versus the non-TRD MDD (adjusted cost difference = $3,377, P<0.001) or non-MDD cohorts (adjusted cost difference = $3,675, P<0.001; Fig 3 and Table 2).”
> “The TRD cohort had higher rates of PPPY behavioral health-related HRU relative to the non-TRD MDD cohort (e.g., inpatient visits: IRR = 1.49) and versus the non-MDD cohort (e.g., inpatient visits: IRR = 3.84, all P<0.001).”

Source: [Pilon et al. (2019b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6786597/)

<a id="topic-2.2.1.8.2-8"></a>

###### Medicare beneficiaries: published correction of the abstract results

> “In the Results subsection of the Abstract. there are numbers reported which are inconsistent with those of the main text.”
> “The TRD cohort had significantly higher total PPPY healthcare costs than the non-TRD MDD cohort ($25,059 vs. $19,945, adjusted cost difference = $3,377) and non-MDD cohort ($25,059 vs. $14,410, adjusted cost difference = $3,675, all P<0.001).”

Source: [Pilon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8016289/)

<a id="topic-2.2.1.8.2-9"></a>

###### Medicare beneficiaries aged 65 years or older: resource use, costs, and hospitalization risk

> “After matching, 178 patients from each cohort were analyzed.”
> “During 12 months of follow-up, TRD patients had higher use of different antidepressants and antipsychotics, higher inpatient and emergency room visits, longer inpatient stays, and higher total healthcare costs ($24,543 versus $16,059, $8,058) than non-TRD MDD and non-MDD cohorts, respectively (all p <0.05).”
> “Risk of initial hospitalization was higher in the TRD (hazard ratio [HR] = 3.60, 95% confidence interval [CI] = 2.08-6.23) and non-TRD MDD cohorts (HR = 1.82, 95% CI = 1.02-3.25) than the non-MDD cohort.”

Source: [Benson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31735488/)

<a id="topic-2.2.1.8.2-10"></a>

###### Medicaid beneficiaries: resource use and costs

> “TRD beneficiaries had higher HRU than 1:1 matched non-TRD-MDD (e.g., inpatient visits: IRR = 1.41) and non-MDD beneficiaries (N = 14,710 per cohort; e.g., inpatient visits: IRR = 3.42, p < 0.01).”
> “TRD beneficiaries incurred greater costs versus non-TRD-MDD (CD = US$4382) and non-MDD beneficiaries (CD = US$8294; p < 0.05).”

Source: [Pilon et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30734581/)

<a id="topic-2.2.1.8.2-11"></a>

###### Medicaid beneficiaries initiating esketamine, electroconvulsive therapy, or transcranial magnetic stimulation: mental health-related resource use and costs

> “ESK cohort included 151 patients (mean age: 40.6 years; female: 70.2%), ECT cohort included 198 patients (mean age: 43.0 years; female: 60.6%), and TMS cohort included 140 patients (mean age: 39.5 years; female: 65.0%).”
> “Mean MH-related acute care costs during the follow-up period trended lower in ESK cohort (IP: $76; ED: $29) relative to ECT (IP: $1,547; ED: $45) and TMS cohorts (IP: $238; ED: $123).”
> “Outpatient costs in ESK cohort ($1,632) exceeded OP costs in ECT ($1,023) and TMS ($1,051) cohorts.”
> “This finding should be interpreted with caution, given potential differences in patient profiles, clinical history and setting of administration.”

Source: [Clemens et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/43010363/)

<a id="topic-2.2.1.8.2-12"></a>

###### Veterans Health Administration: resource use and health care costs

> “After 1:1 exact matching, 10,449 patients were included in each cohort (mean age: 48.9 years).”
> “Patients with TRD had higher per patient per year (PPPY) HRU than non-TRD MDD (all-cause inpatient visits: incidence rate ratio [IRR]: 1.70 [95% confidence interval: 1.57-1.83]) and non-MDD (IRR: 5.04 [95% confidence interval: 4.51-5.63]), and incurred higher total all-cause health care costs PPPY than non-TRD MDD (mean difference: $5,906) and non-MDD (mean difference: $11,873; all p<.0001).”

Source: [Szukis et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33879005/)

<a id="topic-2.2.1.8.2-13"></a>

###### Incremental health care and productivity costs across studies: systematic review of United States data, 1996 to 2013

> “Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression.”
> “At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion.”

Source: [Mrazek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24789696/)

<a id="topic-2.2.1.8.2-14"></a>

###### Costs across increasing levels of non-response: systematic review

> “The 12 studies on economic burden found an association between increasing levels of TRD/non-response and elevations in direct and indirect costs.”

Source: [Johnston et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30195173/)

<a id="topic-2.2.1.8.2-15"></a>

###### Inpatient bed-days, outpatient visits, and lost workdays: population-based cohort in Stockholm, Sweden

> “Of these, 12 793 episodes (11%) fulfilled criteria for TRD.”
> “Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date.”
> “This cohort study found that, compared with patients with MDD and no TRD episodes, patients with TRD episodes had higher prevalence of psychiatric comorbid conditions, twice the utilization of outpatient health care resources, 3 times the number of inpatient bed-days, and 23% higher all-cause mortality.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.8.2-16"></a>

###### Health care professional visits versus the general population: five European countries

> “Additionally, healthcare resource utilization was significantly higher for TRD patients more so than nTRD, compared to the general population, especially for healthcare professional visits (odds ratio nTRD = 5.4; TRD = 15.9, p < 0.001).”

Source: [Jaffe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6686569/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Treatment-resistant depression on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Indirect and direct costs for employed caregivers of persons with TRD: national population-based survey

> “Screening identified 169 TRD caregivers and 1070 No TRD caregivers providing 23.3 and 14.6 mean weekly caregiving hours, respectively.”
> “Adjusted annual indirect cost estimates were $11,121 for caregivers of TRD and $7761 for caregivers in the No TRD group (P ≤ 0.0001).”
> “At-work productivity loss (presenteeism) was the largest component.”
> “Adjusted annual direct cost estimates were $29,805 for caregivers of TRD and $20,642 for caregivers in the No TRD group (P ≤ 0.0001).”

Source: [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver work absences, reduced hours, leave, and out-of-pocket expenses

> “Caregiving-related work absences were higher in the TRD group (5.0 days vs 3.2 days).”
> “A larger proportion of caregivers in the TRD group reduced their work hours (29.0% vs 11.5%), resulting in an unadjusted, annualized cost of $1369 versus $512 (P < 0.0001).”
> “Finally, the proportion taking a leave of absence was higher in the TRD group as well (11.1% vs 5.2%), resulting in a difference in the unadjusted annualized cost ($4367 vs $1047; P < 0.0001).”
> “The proportion of caregivers in the TRD group with out-of-pocket expenses for caregiving services was double the rate of the No TRD group (45.5% vs 22.2%; P < 0.0001).”
> “In the TRD group, the percentage of caregivers who were spouses or partners to care recipients was twice as high as the No TRD group (27.8% vs 12.7%); (difference in relationship type P ≤ 0.0001).”

Source: [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver mental health and study limitations

> “Caregivers in the TRD group also reported more frequent depression symptoms of anhedonia (ie, loss of the capacity to experience pleasure) and depressed mood (P ≤ 0.0001), and 16.8% versus 6.7% screened positive for depression (P ≤ 0.001).”
> “It was cross-sectional and the sample, though large, was a convenience sample.”
> “This was the first time that self-report has been used to operationalize the TRD criteria, and though following rigorous survey methods, the assessment tool was not tested for reliability and validity.”

Source: [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/)

<a id="topic-2.2.1.8.3-4"></a>

###### Income loss among household members of adults with MDD in the United States in 2019

> “An estimated 17 million adults without MDD live in a household with an adult with MDD and the total incremental loss in annual income among these individuals was estimated at $80.1 billion ($4048 per adult with MDD; Supplementary Table S8).”

Source: [Greenberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499687/)

<a id="topic-2.2.1.8.3-5"></a>

###### Psychiatric, educational, and work-related outcomes in offspring of parents with TRD: Swedish national registers

> “Parents and their 2,359 first-born offspring, aged 6–15 years when parents were defined with TRD, were closely matched 1:1 with parent-offspring pairs with other parental depression as well as with parent-offspring pairs from the general population.”
> “Adjusted hazard ratios for offspring of parents with TRD were: depression 4.6 (95%CI 3.2–6.5); contact with psychiatry 3.3 (2.8–4.0); psychiatric medication 3.6 (3.0–4.2); suicide attempt 3.2 (1.9–5.5); sick leave for mental health reasons 2.3 (1.1–4.6); and disability pension 4.2 (2.2–8.1).”
> “The adjusted odds ratio for non-completion of secondary school when expected was 2.1 (1.5–2.9).”
> “In direct comparisons between offspring of parents with TRD vs. other depression, relative risks for all outcomes were similar, with no statistically significant differences.”

Source: [Brenner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12996023/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Antidepressant Optimization, Switching, and Combination

<a id="topic-2.2.2.1.1-1"></a>

###### CANMAT guideline: response and remission after first and second antidepressant trials

> “In real-world populations, approximately half of patients with MDD achieve response (>50% reduction in symptom severity) after 8 weeks of antidepressant monotherapy, while about a third attain full symptom remission; only a quarter of nonremitters who receive a second pharmacological treatment will reach remission.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.1-2"></a>

###### CANMAT guideline: dose optimization, switching, and sequencing of adjunctive strategies

> “Optimizing the antidepressant dose is an important first step.”
> “Higher than minimal therapeutic doses are more effective (to a plateau around the equivalent of 50 mg of fluoxetine) but less well-tolerated”
> “The evidence for the efficacy of switching antidepressants is inconsistent. Meta-analyses show that switching to another antidepressant is not superior to continuing the same one and there appears to be diminishing response rates for antidepressant monotherapy beyond the first switch.”
> “Moreover, RCTs directly comparing switching to adjunctive strategies have shown that adjunctive strategies have superior outcomes and often similar tolerability.”
> “Hence, while balancing individual risks, benefits, and patient preference, CANMAT recommends that adjunctive strategies be considered earlier in the treatment algorithm, after limited response to the first or second antidepressant trial”
> “Switching should be considered first when there is no response to the initial antidepressant or when the first medication has troublesome side effects. Adjunctive strategies should be considered first when there is a partial response to the initial antidepressant and there are minimal or no tolerability issues with the first medication.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.1-3"></a>

###### CANMAT guideline: tricyclic antidepressants, MAOIs, and adjunctive antidepressants

> “Hence, TCAs and MAOIs should be considered as therapeutic options when first-line and second-line medication treatments are not effective, with patients monitored carefully for side effects and potential for drug interactions.”
> “Compared to serotonin-dopamine activity-modulating agents, antidepressants generally have a more favourable side effect profile when used as adjunctive treatment, but the evidence for efficacy is less robust.”
> “Adding mirtazapine/mianserin (antagonists of presynaptic α2-adrenoceptors) is superior to other combinations. Large RCTs have shown evidence for the effectiveness of adjunctive bupropion but the meta-analyses are inconclusive. Hence, these are recommended as second-line treatments for DTD.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.1-4"></a>

###### NICE guideline: options after no or limited response to antidepressant medication

> “If a person's depression has had no or a limited response to treatment with antidepressant medication alone, and no obvious cause can be found and resolved, discuss further treatment options with the person and make a shared decision on how to proceed based on their clinical need and preferences.”
> “increasing the dose of the current medication (within the licensed dose range) if the medication is well tolerated; be aware that higher doses of antidepressants may not be more effective and can increase the frequency and severity of side effects; ensure follow-up and frequent monitoring of symptoms and side effects after dose increases.”
> “switching to another medication in the same class (for example, another SSRI)”
> “switching to a medication of a different class (for example, an SSRI, SNRI, or in secondary care a TCA or MAOI); take into account that:”
> “TCAs are dangerous in overdose, although lofepramine has the best safety profile”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.1-5"></a>

###### NICE guideline: combining antidepressants

> “If a person whose depression has had no response or a limited response to antidepressant medication does not want to try a psychological therapy, and instead wants to try a combination of medications, explain the possible increase in their side-effect burden.”
> “adding an additional antidepressant medication from a different class (for example, adding mirtazapine or trazodone to an SSRI)”
> “Be aware that some combinations of classes of antidepressants are potentially dangerous and should be avoided (for example, a SSRI, SNRI or TCA with a MAOI)”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.1-6"></a>

###### VA/DoD guideline: next steps after partial or no response to initial pharmacotherapy

> “For patients with MDD who have demonstrated partial or no response to an adequate trial of initial pharmacotherapy, we suggest (not rank ordered):”
> “Switching to another antidepressant (including TCAs, MAOIs, or those in Recommendation 12)”
> “Switching to psychotherapy”
> “Augmenting with a psychotherapy”
> “Augmenting with a second-generation antipsychotic”
> “(Weak for | Reviewed, Amended)”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### VA/DoD guideline: evidence on dose escalation, switching, and antidepressant combinations

> “An SR by Braun et al. (2020) found no clinically relevant dose-effects gradients for SSRIs and that dropout rates increased with dose, primarily due to side effects.”
> “In general, monotherapy with first-line antidepressants (e.g., SSRIs, SNRIs, bupropion, mirtazapine) is preferable to combination treatment with two antidepressants because of the increased potential for drug-drug interactions, adverse effects, and lack of clinical benefit.”
> “An SR by Bschor et al. (2018) and an RCT by Tadic et al. (2016) found no difference in antidepressant efficacy, symptom response, remission, adverse effects, and functional status between switching and continuation of antidepressant treatment.”
> “An SR by Davies et al. (2019) found no difference in depressive symptoms, remission, adverse events, QoL, and functional status in patients who received mirtazapine augmentation versus placebo augmentation.”
> “There was insufficient evidence to recommend bupropion even though the risks associated with augmentation are considered lower than with SGA’s, and in clinical practice, bupropion is preferred over an SGA.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.1-8"></a>

###### ACP guideline: second-line options after nonresponse to a second-generation antidepressant

> “ACP suggests one of the following options for patients in the acute phase of moderate to severe major depressive disorder who did not respond to initial treatment with an adequate dose of a second-generation antidepressant: • Switching to or augmenting with cognitive behavioral therapy (conditional recommendation; low-certainty evidence) • Switching to a different second-generation antidepressant or augmenting with a second pharmacologic treatment (see Clinical Considerations) (conditional recommendation; low-certainty evidence)”

Source: [Qaseem et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36689752/)

<a id="topic-2.2.2.1.1-9"></a>

###### Switching after SSRI failure: remission and response with bupropion, sertraline, or venlafaxine

> “We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg.”
> “Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events.”
> “After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant.”

Source: [Rush et al. (2006a)](https://pubmed.ncbi.nlm.nih.gov/16554525/)

<a id="topic-2.2.2.1.1-10"></a>

###### Augmentation after SSRI failure: bupropion or buspirone added to citalopram

> “We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without remission despite a mean of 11.9 weeks of citalopram therapy (mean final dose, 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augmentation and 286 to receive buspirone (at a dose of up to 60 mg per day) as augmentation.”
> “The sustained-release bupropion group and the buspirone group had similar rates of HRSD-17 remission (29.7 percent and 30.1 percent, respectively), QIDS-SR-16 remission (39.0 percent and 32.9 percent), and QIDS-SR-16 response (31.8 percent and 26.9 percent).”
> “a lower dropout rate due to intolerance (12.5 percent vs. 20.6 percent, P<0.009).”

Source: [Trivedi et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16554526/)

<a id="topic-2.2.2.1.1-11"></a>

###### Remission and relapse across four sequential treatment steps

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”
> “When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.2.1.1-12"></a>

###### Reanalysis of cumulative remission with the protocol-specified rating scale

> “In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria.”
> “Combining STAR*D’s HRSD-defined remissions with those from the non-stipulated measure increased its cumulative remission rate from 35.0% to 41.3%.”

Source: [Pigott et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/)

<a id="topic-2.2.2.1.1-13"></a>

###### Fourth-step treatment: MAOI versus venlafaxine plus mirtazapine

> “Remission rates were not significantly different between the two treatment groups (6.9% for the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group).”
> “Tranylcypromine was associated with significantly less symptom reduction and greater attrition due to intolerance.”

Source: [McGrath et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16946177/)

<a id="topic-2.2.2.1.1-14"></a>

###### Switching to bupropion versus bupropion or aripiprazole augmentation in veterans

> “Remission rates at 12 weeks were 22.3% (n = 114) for the switch group, 26.9% (n = 136)for the augment-bupropion group, and 28.9% (n = 146) for the augment-aripiprazole group.”
> “The augment-aripiprazole group exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60]; P = .02), but other remission comparisons were not significant.”
> “Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n = 124] vs 16.6% in the augment-aripiprazole group [n = 84]; and 22.5% in augment-bupropion group [n = 114]).”

Source: [Mohamed et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5817471/)

<a id="topic-2.2.2.1.1-15"></a>

###### Augmentation versus switching in adults aged 60 years or older

> “Remission occurred in 28.9% of patients in the aripiprazole-augmentation group, 28.2% in the bupropion-augmentation group, and 19.3% in the switch-to-bupropion group. The rate of falls was highest with bupropion augmentation.”
> “In step 1, approximately 70% of the patients were adherent to aripiprazole augmentation and bupropion augmentation, but approximately 40% were adherent to the use of bupropion alone.”

Source: [Lenze et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/)

<a id="topic-2.2.2.1.1-16"></a>

###### Combining antidepressants versus monotherapy: meta-analysis

> “Thirty-nine RCTs including 6751 patients were eligible. Combination treatment was statistically significantly associated with superior treatment outcomes relative to monotherapy (SMD = 0.31; 95% CI, 0.19-0.44). Combining a reuptake inhibitor with an antagonist of presynaptic α2-autoreceptors was superior to other combinations (SMD = 0.37; 95% CI, 0.19-0.55).”
> “Numbers of dropouts and dropouts due to adverse events did not differ between treatments. Studies were heterogeneous, and there was indication of publication bias”

Source: [Henssler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8851370/)

<a id="topic-2.2.2.1.1-17"></a>

###### Mirtazapine added to an SSRI or SNRI in treatment-resistant depression in primary care

> “Beck depression inventory II scores at 12 weeks were lower in the mirtazapine group after adjustment for baseline scores and minimisation or stratification variables, although the confidence interval included the null (mean (SD) scores at 12 weeks: 18.0 (12.3) in the mirtazapine group, 19.7 (12.4) in the placebo group; adjusted difference between means −1.83 (95% confidence interval −3.92 to 0.27); P=0.09). Adverse effects were more common in the mirtazapine group and were associated with the participants stopping the trial drug.”

Source: [Kessler et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6207929/)

Additional sources: [American Psychiatric Association (2010)](https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf); [Qaseem et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41802255/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Second-generation Antipsychotic Augmentation

<a id="topic-2.2.2.1.2-1"></a>

###### CANMAT guideline: line of treatment for adjunctive atypical antipsychotics

> “Adjunctive treatment with serotonin-dopamine activity modulators (also known as atypical antipsychotic agents) has the most consistent evidence for efficacy in DTD (Table 7.2).”
> “Aripiprazole and brexpiprazole are listed as first-line agents because of their efficacy and tolerability profile. Cariprazine is recommended as the second-line because there are fewer studies compared to the other agents.”
> “Some agents with Level 1 evidence for efficacy are recommended as second-line treatments because of the increased risk of certain side effects, including olanzapine (weight gain and metabolic side effects), quetiapine-XR (sedation and metabolic side effects), and risperidone (hyperprolactinemia, sexual side effects, and extrapyramidal symptoms).”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.2-2"></a>

###### CANMAT guideline: adverse effects and duration of adjunctive treatment

> “Common side effects with aripiprazole and brexpiprazole include akathisia and weight gain.”
> “There are also potential long-term risks with these medications, such as tardive dyskinesia, although the risk is lower compared to older antipsychotics and is mitigated by the lower dosing used for MDD. In studies of conditions other than MDD, long-term use of these agents in older age may be associated with increased mortality.”
> “Finally, there is little evidence available for maintenance treatment with adjunctive agents, so it is unclear how long adjunctive medications should be continued.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.2-3"></a>

###### NICE guideline: antipsychotic augmentation and monitoring

> “combining an antidepressant medication with a second-generation antipsychotic (for example, aripiprazole, olanzapine, quetiapine or risperidone) or lithium”
> “when using an antipsychotic the effects of this on depression, including loss of interest and motivation, should be carefully reviewed.”
> “Before starting an antipsychotic, check the person's baseline pulse and blood pressure, weight, nutritional status, diet, level of physical activity, fasting blood glucose or HbA1c and fasting lipids.”
> “For people with depression who are taking an antipsychotic, consider at each review whether to continue the antipsychotic based on their current physical and mental health risks.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.2-4"></a>

###### VA/DoD guideline: approved agents and adverse effects of augmentation

> “Three atypical antipsychotics are FDA-approved for MDD as adjunctive treatment/augmentation: aripiprazole, brexpiprazole, and quetiapine-XR.”
> “Olanzapine is approved for the treatment of acute treatment-resistant MDD when used in combination with fluoxetine, but olanzapine by itself is not indicated for the treatment of treatment-resistant depression (TRD).”
> “Fair quality evidence found that compared to placebo, aripiprazole had a significantly higher incidence of akathisia and weight gain; olanzapine had a significantly higher incidence of weight gain and sedation; quetiapine had significantly greater weight gain and sedation; and risperidone had greater, but not statistically significant, weight gain when compared to antidepressants plus placebo.”
> “Due to the possibility of additional side effects and the potential for drug-drug interactions with augmentation, SGAs require appropriate monitoring (e.g., glucose, complete blood count, hepatic panel, lipid panel, body mass index, waist circumference, blood pressure, involuntary movements/tardive dyskinesia, slit lamp exam [quetiapine-only]).”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### Aripiprazole label: indication, boxed warning, and adjunctive efficacy

> “Adjunctive Treatment of Major Depressive Disorder (14.3)”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants.”
> “In the two trials (n=381, n=362), ABILIFY was superior to placebo in reducing mean MADRS total scores (Studies 1, 2 in Table 25).”
> “The mean final dose at the end point for the two trials was 10.7 and 11.4 mg/day.”

Source: [Abilify prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

###### Aripiprazole label: change in MADRS total score at week 6

| Study | Placebo-subtracted difference in MADRS change (95% CI) |
| --- | --- |
| Study 1 | “-2.84 (-4.53, -1.15)” |
| Study 2 | “-3.01 (-4.66, -1.37)” |

Source: [Abilify prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

###### Aripiprazole label: adverse reactions in adjunctive trials

> “The incidence of discontinuation due to adverse reactions was 6% for patients treated with adjunctive ABILIFY and 2% for patients treated with adjunctive placebo.”
> “The commonly observed adverse reactions associated with the use of adjunctive ABILIFY in patients with major depressive disorder (incidence of 5% or greater and ABILIFY incidence at least twice that for placebo) were: akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision.”

Source: [Abilify prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

###### Brexpiprazole label: indication, boxed warning, and adjunctive efficacy

> “Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients and young adult patients in short-term studies.”
> “In Studies 1 and 2, REXULTI (plus ADT) 2 mg once daily and 3 mg once daily were superior to placebo plus ADT in reducing mean MADRS total scores.”

Source: [Rexulti prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf)

<a id="topic-2.2.2.1.2-9"></a>

###### Brexpiprazole label: change in MADRS total score at week 6

| Study and dose | Placebo-subtracted difference in MADRS change (95% CI) |
| --- | --- |
| Study 1, 2 mg/day | “-3.2 (-4.9, -1.5)” |
| Study 2, 1 mg/day | “-1.3 (-2.7, 0.1)” |
| Study 2, 3 mg/day | “-2.0 (-3.4, -0.5)” |

Source: [Rexulti prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf)

<a id="topic-2.2.2.1.2-10"></a>

###### Brexpiprazole label: adverse reactions in adjunctive trials

> “Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): Weight increased, somnolence, and akathisia (≥5% and at least twice the rate for placebo)”
> “In Studies 1 and 2, among the adverse reactions that occurred at ≥2% incidence in the patients treated with REXULTI plus ADT, the incidences of akathisia and restlessness increased with increases in dose.”

Source: [Rexulti prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf)

<a id="topic-2.2.2.1.2-11"></a>

###### Quetiapine extended-release label: indication, boxed warning, and adjunctive efficacy

> “Major depressive disorder, adjunctive therapy with antidepressants”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “Increased risk of suicidal thoughts and behavior in children, adolescents and young adults taking antidepressants.”
> “The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in the treatment of MDD was demonstrated in two 6-week placebo-controlled, fixed-dose trials (n=936).”
> “SEROQUEL XR 300 mg once daily as adjunctive treatment to other antidepressant therapy was superior to antidepressant alone in reduction of MADRS total score in both trials. SEROQUEL XR 150 mg once daily as adjunctive treatment was superior to antidepressant therapy alone in reduction of MADRS total score in one trial”

Source: [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.2-12"></a>

###### Quetiapine extended-release label: adverse reactions and metabolic warnings

> “Most common adverse reactions (incidence ≥5% and twice placebo): Adults: somnolence, dry mouth, constipation, dizziness, increased appetite, dyspepsia, weight gain, fatigue, dysarthria, and nasal congestion”
> “Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain”

Source: [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.2-13"></a>

###### Cariprazine label: indication, boxed warning, and adjunctive efficacy

> “Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “VRAYLAR 1.5 mg + ADT was superior to placebo + ADT at end of Week 6 on the MADRS total score. The treatment effect in the VRAYLAR 3 mg per day + ADT group (vs. placebo + ADT) was not statistically significant.”
> “VRAYLAR 2 to 4.5 mg (mean dose was 2.6 mg) + ADT was superior to placebo + ADT at end of Week 8 on the MADRS total score. The treatment effect in the VRAYLAR 1 to 2 mg per day + ADT group (vs. placebo + ADT) was not statistically significant.”

Source: [Vraylar prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204370s014s015s016s017lbl.pdf)

<a id="topic-2.2.2.1.2-14"></a>

###### Cariprazine label: adverse reactions in adjunctive trials

> “Adjunctive treatment of MDD: akathisia, restlessness, fatigue, constipation, nausea, insomnia, increased appetite, dizziness, and extrapyramidal symptoms”

Source: [Vraylar prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204370s014s015s016s017lbl.pdf)

<a id="topic-2.2.2.1.2-15"></a>

###### Olanzapine and fluoxetine label: treatment-resistant depression indication and efficacy

> “Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode)”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “The efficacy of SYMBYAX in acute treatment resistant depression was demonstrated with data from 3 clinical studies (n=579) in adults (18 to 85 years).”
> “Results from this study yielded statistically significant greater reduction in mean total MADRS scores from baseline to endpoint for SYMBYAX versus fluoxetine and olanzapine.”

Source: [Symbyax prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021520s056lbl.pdf)

<a id="topic-2.2.2.1.2-16"></a>

###### Olanzapine and fluoxetine label: adverse reactions and weight gain

> “Most common adverse reactions (≥5% and at least twice that for placebo) in adults: sedation, weight increased, appetite increased, dry mouth, fatigue, edema, tremor, disturbance in attention, blurred vision.”
> “In an analysis of 7 controlled clinical studies, 2 of which were placebo-controlled, the mean weight increase for SYMBYAX-treated patients was greater than placebo-treated patients [4 kg (8.8 lb) vs -0.3 kg (-0.7 lb)]. Twenty-two percent of SYMBYAX-treated patients gained at least 7% of their baseline weight, with a median exposure to event of 6 weeks.”

Source: [Symbyax prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021520s056lbl.pdf)

<a id="topic-2.2.2.1.2-17"></a>

###### Network meta-analysis of augmentation agents: response, remission, and discontinuation

> “A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA.”
> “For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates.”
> “In order of efficacy, T4, aripiprazole, risperidone, quetiapine, olanzapine(fluoxetine), brexpiprazole were statistically significant compared to placebo with RRs ranging from 1.44 (1.00–2.08) for brexpiprazole to 1.91 (1.04–3.52) for T4.”

Source: [Nuñez et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9328668/)

<a id="topic-2.2.2.1.2-18"></a>

###### Meta-analysis of adjunctive atypical antipsychotics: remission, response, and harms

> “All four drugs had statistically significant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48–2.73), OFC (OR, 1.42; 95% CI, 1.01–2.0), quetiapine (OR, 1.79; 95% CI, 1.33–2.42), and risperidone (OR, 2.37; 95% CI, 1.31–4.30). The number needed to treat (NNT) was 19 for OFC and nine for each other drug.”
> “On measures of functioning and quality of life, these medications produced either no benefit or a very small benefit, except for risperidone, which had a small-to-moderate effect on quality of life (g = 0.49).”
> “Adjunctive aripiprazole was frequently associated with akathisia (NNH, 4; 95% CI, 3–6) and also linked to a statistically significant elevation in the occurrence of sedation (NNH, 14; 95% CI, 8–33) and significant weight gain of ≥7% during trials (NNH, 29; 95% CI, 10–119).”
> “Adjunctive quetiapine had a very high rate of reported sedation (NNH, 3; 95% CI, 2–3)”

Source: [Spielmans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3595214/)

<a id="topic-2.2.2.1.2-19"></a>

###### Aripiprazole augmentation in veterans: response and adverse effects

> “Response was greater for the augment-aripiprazole group (74.3%) than for either the switch group (62.4%; RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]).”
> “Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain.”
> “Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach.”

Source: [Mohamed et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5817471/)

<a id="topic-2.2.2.1.2-20"></a>

###### Aripiprazole augmentation in adults aged 60 years or older: well-being and falls

> “The difference in the change from baseline in psychological well-being between the aripiprazole-augmentation group and the switch-to-bupropion group was 2.79 points (95% CI, 0.56 to 5.02)”
> “In step 1, fall rates during the acute phase over a period of approximately 10 weeks were 0.33 per patient in the aripiprazole-augmentation group, 0.55 in the bupropion-augmentation group, and 0.38 in the switch-to-bupropion group (Table 3).”

Source: [Lenze et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Lithium and Thyroid Hormone Augmentation

<a id="topic-2.2.2.1.3-1"></a>

###### CANMAT guideline: lithium and triiodothyronine as second-line adjuncts

> “Both medications were included in a network meta-analysis evaluating all adjunctive options. While both lithium and triiodothyronine had evidence for efficacy, the included RCTs predated 2003, had small sample sizes and involved adjunctive use with TCAs only. Lithium also requires serum level monitoring and triiodothyronine requires monitoring of thyroid levels. Hence, lithium and triiodothyronine continue to be second-line recommendations.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.3-2"></a>

###### NICE guideline: lithium and liothyronine augmentation and lithium monitoring

> “combining an antidepressant medication with a second-generation antipsychotic (for example, aripiprazole, olanzapine, quetiapine or risperidone) or lithium”
> “augmenting antidepressants with electroconvulsive therapy (see the recommendations on electroconvulsive therapy for depression), lamotrigine, or triiodothyronine (liothyronine).”
> “For people with depression taking lithium, assess weight, renal and thyroid function and calcium levels before treatment and then monitor at least every 6 months during treatment, or more often if there is evidence of significant renal impairment.”
> “plasma lithium levels should not exceed 1.0 mmol/L (therapeutic levels for augmentation of antidepressant medication are usually at or above 0.4 mmol/L; consider levels 0.4 to 0.6 mmol/L for older people aged 65 or above)”
> “monitor at each review for signs of lithium toxicity, including diarrhoea, vomiting, coarse tremor, ataxia, confusion and convulsions”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.3-3"></a>

###### VA/DoD guideline: lithium and liothyronine with insufficient evidence for or against

> “Medications with Insufficient Evidence to Support For or Against”
> “Lithium augmentation resulted in a reduction in depressive symptoms with a clinically meaningful NNT of five patients.”
> “However, Papadimitropoulou et al. (2017) found no difference in symptom improvement and remission in patients who received lithium augmentation versus placebo augmentation.”
> “In addition, lithium usage requires monitoring of lithium blood levels (therapeutic blood level is between 0.6 – <1.0 milliequivalents per liter [mEq/L] while potentially toxic blood levels are >1.5 mEq/L), and monitoring of thyroid function.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### VA/DoD guideline: liothyronine remission and cautions

> “Liothyronine augmentation at the dose of 50 µg/day resulted in a remission rate of 25.7% with a mean time to remission of 5.3 weeks in the STAR*D study.”
> “Liothyronine should be prescribed with caution in patients with cardiovascular disease/arrhythmias, diabetes, renal impairment, or untreated adrenal insufficiency.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### Third-step augmentation: lithium versus triiodothyronine

> “A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T(3) (up to 50 mug/day; N=73) for up to 14 weeks.”
> “After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T(3) augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027).”

Source: [Nierenberg et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16946176/)

<a id="topic-2.2.2.1.3-6"></a>

###### Lithium augmentation versus placebo: meta-analysis

> “Nine trials that included 237 patients were selected. The odds ratio for response to lithium vs. placebo in all contrasts combined was 2.89 (95% CI 1.65, 5.05, z=3.72, p=0.0002).”
> “Adjunctive lithium was effective with TCAs (7 contrasts) and with second generation agents (3 contrasts). Discontinuation due to adverse events was infrequent and did not differ between lithium and placebo.”
> “The meta-analysis is limited by the small size and number of trials and limited data for treatment resistant patients.”

Source: [Nelson et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25069082/)

<a id="topic-2.2.2.1.3-7"></a>

###### Network meta-analysis of augmentation agents: lithium and thyroid hormones

> “In order of decreasing efficacy, T3, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine and lisdexamfetamine were statistically significant compared to placebo, with RRs ranging from 1.18 (1.03–1.37) for lisdexamfetamine to 1.90 (1.16–3.11) for T3.”
> “However, we should acknowledge that remission rates were not significant compared to placebo.”
> “Nevertheless, in a post-hoc sub-analysis of only three short-term studies (≤3 weeks) we found that response rates were not significant as compared to placebo (RR= 1.79; 0.48–6.67).”

Source: [Nuñez et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9328668/)

<a id="topic-2.2.2.1.3-8"></a>

###### Thyroid hormone augmentation in unipolar treatment-resistant depression: meta-analysis

> “Based on the screening of these records, we identified 10 studies that met the inclusion criteria (total number of patients = 663). The comparison of response to thyroid hormones vs. placebo resulted in an odds ratio of 1.56 (95% CI: 0.50-4.84). Similarly, the comparison of response to thyroid hormones vs. lithium resulted in an odds ratio of 1.91 (95% CI: 0.85-4.26).”
> “According to this review and meta-analysis, there is not sufficient evidence to support the use of adjunctive thyroid hormones for treatment-resistant unipolar depression.”

Source: [Lorentzen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31977066/)

<a id="topic-2.2.2.1.3-9"></a>

###### Lithium versus quetiapine augmentation over 12 months

> “Participants in the quetiapine group had a significantly lower overall burden of depressive symptom severity than participants in the lithium group (area under the between-group differences curve -68·36 [95% CI -129·95 to -6·76; p=0·0296). Time to discontinuation did not significantly differ between the two groups. Quetiapine was more cost-effective than lithium.”
> “Results of the trial suggest that quetiapine is more clinically effective than lithium as a first-line augmentation option for reducing symptoms of depression in the long-term management of treatment-resistant depression, and is probably more cost-effective than lithium.”

Source: [Cleare et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40113355/)

<a id="topic-2.2.2.1.3-10"></a>

###### Lithium augmentation versus switch to nortriptyline in adults aged 60 years or older

> “Remission occurred in 18.9% of patients in the lithium-augmentation group and 21.5% in the switch-to-nortriptyline group; rates of falling were similar in the two groups.”
> “In our trial, less than 10% of the patients who switched to bupropion or had augmentation with lithium both reached and maintained the target dose and had remission.”

Source: [Lenze et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/)

<a id="topic-2.2.2.1.3-11"></a>

###### Lithium label: boxed warning on toxicity and renal effects

> “Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy”
> “The toxic concentrations for lithium (≥1.5 mEq/L) are close to the therapeutic range (0.8 to 1.2 mEq/L).”
> “Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia.”

Source: [Lithobid prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018027s069lbl.pdf)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Psychotherapy

<a id="topic-2.2.2.1.4-1"></a>

###### CANMAT guideline: psychotherapy after poor response to an initial antidepressant

> “Based on efficacy and low potential for side effects, first-line psychological treatments should be considered early in the treatment course”
> “There are few studies of psychotherapy for patients showing poor response to antidepressants.”
> “Hence, CBT is recommended as a second-line adjunctive treatment, with medications, for DTD.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.4-2"></a>

###### NICE guideline: psychological therapy after no or limited response to medication

> “switching to a psychological therapy (see the section on suggested treatment options for more severe depression)”
> “changing to a combination of psychological therapy (for example, CBT, interpersonal psychotherapy [IPT] or STPP) and medication.”
> “If a person's depression has had no or a limited response to treatment with a combination of antidepressant medication and psychological therapy, discuss further treatment options with the person and make a shared decision on how to proceed based on their clinical need and preferences.”
> “switching to another psychological therapy”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.4-3"></a>

###### VA/DoD guideline: switching to or augmenting with psychotherapy

> “Switching to psychotherapy”
> “Augmenting with a psychotherapy”
> “Combined pharmacotherapy and psychotherapy are options if a response or remission is not achieved with an antidepressant as initial monotherapy.”
> “In an SR by Li et al. (2018) where the comparators were TAU (three RCTs), psychoeducation (one RCT), health enhancement program (one RCT), and medication change (one RCT), which included participants who were receiving pharmacotherapy at baseline, the addition of psychotherapy (i.e., CBT) resulted in improvement in symptoms of depression and remission.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.4-4"></a>

###### VA/DoD guideline: patient burden and access to psychotherapy

> “However, psychotherapy can be burdensome due to a required time commitment and frequent visits. Further, there may be limited access to recommended evidence-based psychotherapies since not all providers have adequate training in them.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.4-5"></a>

###### ACP guideline: switching to or augmenting with cognitive behavioral therapy

> “ACP suggests one of the following options for patients in the acute phase of moderate to severe major depressive disorder who did not respond to initial treatment with an adequate dose of a second-generation antidepressant: • Switching to or augmenting with cognitive behavioral therapy (conditional recommendation; low-certainty evidence)”

Source: [Qaseem et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36689752/)

<a id="topic-2.2.2.1.4-6"></a>

###### Cognitive behavioral therapy added to usual care in primary care: response at 6 months

> “This two parallel-group multicentre randomised controlled trial recruited 469 patients aged 18-75 years with treatment resistant depression (on antidepressants for ≥6 weeks, Beck depression inventory [BDI] score ≥14 and international classification of diseases [ICD]-10 criteria for depression) from 73 UK general practices.”
> “The primary outcome was response, defined as at least 50% reduction in depressive symptoms (BDI score) at 6 months compared with baseline.”
> “95 participants (46%) in the intervention group met criteria for response at 6 months compared with 46 (22%) in the usual care group (odds ratio 3·26, 95% CI 2·10-5·06, p<0·001).”
> “Because of the nature of the intervention it was not possible to mask participants, general practitioners, CBT therapists, or researchers to the treatment allocation.”

Source: [Wiles et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23219570/)

<a id="topic-2.2.2.1.4-7"></a>

###### Cognitive behavioral therapy added to usual care: long-term follow-up and cost-effectiveness

> “Of these, 248 individuals completed a long-term follow-up questionnaire and provided data for the primary outcome (136 in the intervention group vs 112 in the usual care group). At follow-up (median 45·5 months [IQR 42·5-51·1]), the intervention group had a mean BDI-II score of 19·2 (SD 13·8) compared with a mean BDI-II score of 23·4 (SD 13·2) for the usual care group (repeated measures analysis over the 46 months: difference in means -4·7 [95% CI -6·4 to -3·0, p<0·001]).”
> “The average annual cost of trial CBT per participant was £343 (SD 129). The incremental cost-effectiveness ratio was £5374 per QALY gain.”

Source: [Wiles et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26777773/)

<a id="topic-2.2.2.1.4-8"></a>

###### Psychological therapies for treatment-resistant depression: Cochrane review

> “We included six trials (n = 698; most participants were women approximately 40 years of age). All studies evaluated psychotherapy plus usual care (with antidepressants) versus usual care (with antidepressants).”
> “Moderate‐quality evidence for remission from six studies (RR 1.92, 95% CI 1.46 to 2.52; n = 635) and low‐quality evidence for response from four studies (RR 1.80, 95% CI 1.2 to 2.7; n = 556) indicate that psychotherapy was beneficial as an adjunct to usual care over the short term.”
> “High‐quality evidence shows no differential dropout (a measure of acceptability) between intervention and comparator groups over the short term (RR 0.85, 95% CI 0.58 to 1.24; six studies; n = 698).”
> “No evidence currently shows whether switching to a psychotherapy is more beneficial for this patient group than continuing an antidepressant medication regimen.”

Source: [Ijaz et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6494651/)

<a id="topic-2.2.2.1.4-9"></a>

###### Psychotherapy for treatment-resistant depression: meta-analysis and meta-regression

> “Seven different psychotherapies were studied in 21 trials that included a total of 25 comparisons. In three comparisons of psychotherapy v. treatment as usual (TAU) we found no evidence to conclude that there is a significant benefit of psychotherapy as compared with TAU. In 22 comparisons of add-on psychotherapy plus TAU v. TAU only, we found a moderate general effect size of 0.42 (95% CI 0.29-0.54) in favor of psychotherapy plus TAU.”
> “Most frequent investigated treatments were cognitive behavior therapy, interpersonal psychotherapy, mindfulness-based cognitive therapy, and cognitive behavioral analysis system of psychotherapy.”

Source: [van Bronswijk et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30139408/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Esketamine and Ketamine

<a id="topic-2.2.2.1.5-1"></a>

###### CANMAT guideline: second-line adjunctive ketamine and intranasal esketamine

> “which is approved by several regulatory agencies as an add-on treatment to an SSRI/SNRI or other antidepressant, for patients failing at least 2 adequate antidepressant trials.”
> “There is also growing evidence for relapse-prevention efficacy for both medications, with maintenance doses administered every 1 to 4 weeks”
> “However, side effect potential and feasibility issues (i.e., the required monitoring of blood pressure and dissociative side effects) have downgraded adjunctive ketamine and intranasal esketamine to second-line recommendation.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.5-2"></a>

###### VA/DoD guideline: ketamine or esketamine after several pharmacologic trials

> “For patients with MDD who have not responded to several adequate pharmacologic trials, we suggest ketamine or esketamine as an option for augmentation.”
> “(Weak for | Reviewed, New-replaced)”
> “Ketamine is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist that is FDA-approved for general anesthesia.”
> “The Work Group’s confidence in the quality of the evidence was low.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### NICE guideline: esketamine nasal spray not recommended

> “Esketamine nasal spray is not recommended in NICE technology appraisal guidance for treating treatment-resistant depression.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.5-4"></a>

###### ICER assessment: esketamine and intravenous ketamine as comparators for psilocybin

> “In patients with persistent symptoms, recommended options include esketamine (S-ketamine), ketamine (used off-label for TRD), or repetitive transcranial magnetic stimulation (rTMS”
> “Esketamine (SPRAVATO®, Janssen) / Intravenous (IV) ketamine, an anesthetic agent used off-label for TRD”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.1.5-5"></a>

###### Esketamine FDA-approved indications, including monotherapy

> “SPRAVATO is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated for the treatment of:”
> “Treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant.”
> “Indications and Usage (1) 01/2025”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

###### Esketamine dosing in treatment-resistant depression

> “The recommended dosage of SPRAVATO for the treatment of TRD in adults as monotherapy or in conjunction with an oral antidepressant is shown in Table 1.”
> “Weeks 1 to 4: Administer twice per week Weeks 5 to 8: Administer once weekly Week 9 and after: Administer every 2 weeks or once weekly*”
> “Dosing frequency should be individualized to the least frequent dosing to maintain remission/response.”
> “Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment.”
> “Nasal Spray: 28 mg of esketamine per device.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

###### Esketamine boxed warning

> “WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS”
> “Because of the risks of sedation, dissociation, and respiratory depression, patients must be monitored for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting”
> “SPRAVATO has the potential to be abused and misused.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

###### Esketamine REMS and post-dose monitoring

> “SPRAVATO is available only through a restricted program under a REMS called the SPRAVATO REMS because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse and misuse”
> “Healthcare settings must be certified in the program and ensure that SPRAVATO is: − Only dispensed and administered in healthcare settings.”
> “Administered by patients under the direct observation of a healthcare provider and that patients are monitored by a healthcare provider for at least 2 hours after administration of SPRAVATO”
> “Pharmacies must be certified in the REMS and must only dispense SPRAVATO to healthcare settings that are certified in the program.”
> “During and after SPRAVATO administration at each treatment session, observe the patient for at least 2 hours until the patient is safe to leave”
> “Before SPRAVATO administration, instruct patients not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

###### Esketamine adverse reactions, contraindications, and blood pressure monitoring

> “The most commonly observed adverse reactions (incidence ≥5% and at least twice that of placebo):”
> “TRD: dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, blood pressure increased, vomiting, feeling drunk, and headache.”
> “In clinical trials, 48% to 61% of SPRAVATO-treated patients developed sedation based on the Modified Observer’s Assessment of Alertness/Sedation scale (MOAA/S)”
> “61% to 84% of SPRAVATO-treated patients developed dissociative or perceptual changes based on the Clinician-Administered Dissociative States Scale”
> “Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation”
> “After dosing with SPRAVATO, reassess blood pressure at approximately 40 minutes (which corresponds with the Cmax) and subsequently as clinically warranted.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

###### Esketamine monotherapy study: change in MADRS total score at Day 28

> “patients in Study 3 were randomized in a 1:1:2 ratio to receive twice weekly doses of intranasal SPRAVATO 56 mg or 84 mg or intranasal placebo for four weeks.”
> “SPRAVATO 56 mg and 84 mg monotherapy demonstrated statistical superiority on the primary efficacy measure compared to placebo nasal spray”
> “SPRAVATO (56 mg)† 86 37.5 (5.2) -11.4 (1.2) -5.1 (-7.9; -2.3) SPRAVATO (84 mg)† 95 36.6 (4.5) -13.0 (1.2) -6.8 (-9.5; -4.1) Placebo nasal spray 197 37.5 (4.9) -6.3 (0.8)”
> “The effect of SPRAVATO (56 mg and 84 mg) was observed at Day 2 (approximately 24 hours) and remained through Day 28.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-11"></a>

###### TRANSFORM-2: esketamine plus a new oral antidepressant at Day 28

> “The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively.”
> “Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase.”
> “Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64)”
> “7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event.”

Source: [Popova et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31109201/)

<a id="topic-2.2.2.1.5-12"></a>

###### TRANSFORM-3: esketamine in adults aged 65 years and older

> “For the primary endpoint, the median-unbiased estimate of the treatment difference (95% CI) was -3.6 (-7.20, 0.07); weighted combination test using MMRM analyses z = 1.89, two-sided p = 0.059.”
> “Esketamine/antidepressant did not achieve statistical significance for the primary endpoint.”

Source: [Ochs-Ross et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31734084/)

<a id="topic-2.2.2.1.5-13"></a>

###### SUSTAIN-1: relapse prevention with continued esketamine

> “Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse (log-rank P = .003, number needed to treat [NNT], 6).”
> “Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84) among patients who achieved stable remission and 70% (HR, 0.30; 95% CI, 0.16-0.55) among those who achieved stable response compared with antidepressant and placebo treatment.”

Source: [Daly et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6551577/)

<a id="topic-2.2.2.1.5-14"></a>

###### SUSTAIN-3: long-term safety and maintenance of response

> “At the interim data cutoff (01 December 2020), 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance.”
> “Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis.”
> “with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively.”
> “Serious adverse events were reported for 171 (14.9%) of the 1148 participants during SUSTAIN-3, over 2769 cumulative patient-years.”

Source: [Zaki et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10267177/)

<a id="topic-2.2.2.1.5-15"></a>

###### ESCAPE-TRD: esketamine compared with extended-release quetiapine augmentation

> “Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group.”
> “More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients [14.1%]).”
> “In an open-label, single-blind (with raters unaware of group assignments), multicenter, phase 3b, randomized, active-controlled trial”

Source: [Reif et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37792613/)

<a id="topic-2.2.2.1.5-16"></a>

###### ELEKT-D: intravenous ketamine compared with electroconvulsive therapy

> “During an initial 3-week treatment phase, patients received either ECT three times per week or ketamine (0.5 mg per kilogram of body weight over 40 minutes) twice per week.”
> “A total of 403 patients underwent randomization at five clinical sites; 200 patients were assigned to the ketamine group and 203 to the ECT group.”
> “A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response (difference, 14.2 percentage points; 95% confidence interval, 3.9 to 24.2; P<0.001 for the noninferiority of ketamine to ECT).”
> “ECT was associated with musculoskeletal adverse effects, whereas ketamine was associated with dissociation.”

Source: [Anand et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37224232/)

<a id="topic-2.2.2.1.5-17"></a>

###### Ketamine and esketamine: Cochrane meta-analysis

> “The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence).”
> “Esketamine treatment likely results in a large increase in participants achieving remission at 24 hours compared with placebo (OR 2.74, 95% CI 1.71 to 4.40; n = 894, studies = 5, moderate-certainty evidence).”
> “The effects of ketamine lasted no more than one week after treatment and clearly disappeared after two weeks.”
> “Esketamine caused a lot more side effects than placebo.”

Source: [Dean et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434915/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Repetitive Transcranial Magnetic Stimulation

<a id="topic-2.2.2.1.6-1"></a>

###### CANMAT guideline: rTMS and theta burst protocols

> “Repetitive TMS shows efficacy for DTD, with response rates of 40% to 50%”
> “High-frequency (5 Hz or higher) rTMS delivered over the left dorsolateral prefrontal cortex (DLPFC) has the largest evidence base and is recommended as a first-line protocol, along with low-frequency (1 Hz or lower) rTMS delivered over the right DLPFC.”
> “TBS is recommended as a first-line protocol”
> “Accelerated iTBS to the left DLPFC has evidence for efficacy and a large RCT found no significant differences between accelerated bilateral TBS and high frequency rTMS.”
> “Unlike ECT, rTMS does not require anaesthesia and has no cognitive side effects.”
> “Finally, except in emergent situations as mentioned above, rTMS should generally be considered before ECT, given its less invasive nature and that individuals may continue to work or attend school while undergoing rTMS.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.6-2"></a>

###### VA/DoD guideline: rTMS after two or more pharmacologic trials

> “For patients who have demonstrated partial or no response to two or more adequate pharmacologic treatment trials, we suggest offering repetitive transcranial magnetic stimulation for treatment.”
> “(Weak for | Reviewed, Amended)”
> “The NNT for response is between 3.4 and 9 patients, and the NNT for remission was between five and seven patients.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.6-3"></a>

###### NICE interventional procedures guidance on rTMS

> “The evidence on repetitive transcranial magnetic stimulation for depression shows no major safety concerns.”
> “Repetitive transcranial magnetic stimulation for depression may be used with normal arrangements for clinical governance and audit.”

Source: [NICE (2015)](https://www.nice.org.uk/guidance/htg396/chapter/1-Recommendations)

<a id="topic-2.2.2.1.6-4"></a>

###### Pivotal sham-controlled trial of left prefrontal TMS

> “In a double-blind, multisite study, 301 medication-free patients with major depression who had not benefited from prior treatment were randomized to active (n = 155) or sham TMS (n = 146) conditions.”
> “Remission rates were approximately twofold higher with active TMS at week 6 and significant on the MADRS and HAMD24 scales (but not the HAMD17 scale).”
> “Active TMS was well tolerated with a low dropout rate for adverse events (4.5%) that were generally mild and limited to transient scalp discomfort or pain.”

Source: [O'Reardon et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17573044/)

<a id="topic-2.2.2.1.6-5"></a>

###### OPT-TMS: sham-controlled trial in antidepressant-free outpatients

> “Primary efficacy analysis revealed a significant effect of treatment on the proportion of remitters (14.1% active rTMS and 5.1% sham) (P = .02).”
> “The number needed to treat was 12. Most remitters had low antidepressant treatment resistance.”

Source: [George et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20439832/)

<a id="topic-2.2.2.1.6-6"></a>

###### THREE-D: intermittent theta burst compared with 10 Hz rTMS

> “Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered in 3 min, versus 37·5 min for a standard 10 Hz treatment session.”
> “Between Sept 3, 2013, and Oct 3, 2016, we randomly allocated 205 participants to receive 10 Hz rTMS and 209 participants to receive iTBS.”
> “In patients with treatment-resistant depression, iTBS was non-inferior to 10 Hz rTMS for the treatment of depression.”
> “The most common treatment-related adverse event was headache in both groups (10 Hz rTMS: 131 [64%] of 204; iTBS: 136 [65%] of 208).”

Source: [Blumberger et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29726344/)

<a id="topic-2.2.2.1.6-7"></a>

###### Network meta-analysis of non-surgical brain stimulation

> “113 trials (262 treatment arms) that randomised 6750 patients (mean age 47.9 years; 59% women) with major depressive disorder or bipolar depression met the inclusion criteria.”
> “low frequency right rTMS (3.65, 2.13 to 6.24), intermittent theta burst stimulation (3.20, 1.45 to 7.08), high frequency left rTMS (3.17, 2.29 to 4.37)”
> “All treatment strategies were at least as acceptable as sham therapy.”

Source: [Mutz et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6435996/)

<a id="topic-2.2.2.1.6-8"></a>

###### Stanford neuromodulation therapy: FDA clearance

> “The Magnus Neuromodulation System with SAINT Technology is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.”
> “Regulation Name: Repetitive Transcranial Magnetic Stimulation System Regulatory Class: Class II”

Source: [FDA SAINT Neuromodulation System clearance (2022)](https://www.accessdata.fda.gov/cdrh_docs/pdf22/K220177.pdf)

<a id="topic-2.2.2.1.6-9"></a>

###### Stanford neuromodulation therapy: initial sham-controlled trial

> “The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT).”
> “At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT.”
> “The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group.”

Source: [Cole et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34711062/)

<a id="topic-2.2.2.1.6-10"></a>

###### Stanford neuromodulation therapy: confirmatory sham-controlled trial

> “In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT.”
> “At 1-month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants”

Source: [Kratter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805067/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Electroconvulsive Therapy

<a id="topic-2.2.2.1.7-1"></a>

###### CANMAT guideline: efficacy, course, and cognitive effects of ECT

> “ECT remains one of the most effective treatment options for patients with TRD.”
> “ECT has demonstrated evidence of efficacy and tolerability in the treatment of depressive episodes, with response rates ranging from 65% to 75%”
> “An acute course of ECT usually requires 6 to 12 sessions, with no difference in response outcomes between sessions given twice or thrice weekly”
> “Adverse effects on cognition are of most concern, although modern ECT techniques, including unilateral electrode placement and refined electrical dosing, have reduced both the incidence and severity of cognitive side effects.”
> “Nevertheless, some patients report significant and distressing gaps in autobiographical memory long after ECT, and the discrepancy between cognitive performance and subjective memory dysfunction remains controversial.”
> “Although ECT has high response rates during acute treatment, recurrence occurs in 60% to 80% of patients at 6-month follow-up.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.7-2"></a>

###### VA/DoD guideline: ECT for severe depression

> “We recommend offering electroconvulsive therapy (ECT) with or without psychotherapy for patients with severe MDD and any of the following conditions:”
> “A history of a poor response or intolerable side effects to multiple antidepressants”
> “(Strong for | Reviewed, Not changed)”
> “Symptom improvement with ECT is short-term and should be followed by maintenance treatment with antidepressants, or if antidepressants are not tolerated, repeated treatment with ECT.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.7-3"></a>

###### NICE guideline: ECT for severe depression

> “Consider electroconvulsive therapy (ECT) for the treatment of severe depression if:”
> “other treatments have been unsuccessful (see the recommendations on further-line treatment).”
> “Make sure people with depression who are going to have ECT are fully informed of the risks, and of the risks and benefits specific to them.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.7-4"></a>

###### Meta-analysis of ECT compared with simulated ECT and pharmacotherapy

> “Real ECT was significantly more effective than simulated ECT (six trials, 256 patients, standardised effect size [SES] -0.91, 95% CI -1.27 to -0.54).”
> “Treatment with ECT was significantly more effective than pharmacotherapy (18 trials, 1144 participants, SES -0.80, 95% CI -1.29 to -0.29).”

Source: [UK ECT Review Group (2003)](https://pubmed.ncbi.nlm.nih.gov/12642045/)

<a id="topic-2.2.2.1.7-5"></a>

###### ECT remission after antidepressant pharmacotherapy failure

> “Seven studies were included in this meta-analysis: the overall remission rate amounts to 48.0% (281/585) for patients with and 64.9% (242/373) for patients without previous pharmacotherapy failure.”

Source: [Heijnen et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20814336/)

<a id="topic-2.2.2.1.7-6"></a>

###### Network meta-analysis: response with ECT compared with sham

> “bitemporal ECT (summary odds ratio 8.91, 95% confidence interval 2.57 to 30.91), high dose right unilateral ECT (7.27, 1.90 to 27.78)”

Source: [Mutz et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6435996/)

<a id="topic-2.2.2.1.7-7"></a>

###### ELEKT-D: ECT compared with intravenous ketamine, including memory outcomes

> “A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response (difference, 14.2 percentage points; 95% confidence interval, 3.9 to 24.2; P<0.001 for the noninferiority of ketamine to ECT).”
> “ECT appeared to be associated with a decrease in memory recall after 3 weeks of treatment (mean [±SE] decrease in the T-score for delayed recall on the Hopkins Verbal Learning Test-Revised, -0.9±1.1 in the ketamine group vs. -9.7±1.2 in the ECT group; scores range from -300 to 200, with higher scores indicating better function) with gradual recovery during follow-up.”

Source: [Anand et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37224232/)

<a id="topic-2.2.2.1.7-8"></a>

###### Objective cognitive performance after ECT

> “Twenty-four cognitive variables (84 studies, 2981 patients) were meta-analyzed. No standardized retrograde amnesia tests were identified.”
> “Significant decreases in cognitive performance were observed 0 to 3 days after ECT in 72% of variables”
> “Cognitive abnormalities associated with ECT are mainly limited to the first 3 days posttreatment.”

Source: [Semkovska and McLoughlin (2010)](https://pubmed.ncbi.nlm.nih.gov/20673880/)

<a id="topic-2.2.2.1.7-9"></a>

###### Relapse after successful ECT

> “In modern era studies of continuation pharmacotherapy, 51.1% (95% CI=44.7–57.4%) of patients relapsed by 12 months following successful initial treatment with ECT, with the majority (37.7%, 95% CI=30.7–45.2%) relapsing within the first 6 months.”

Source: [Jelovac et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799066/)

Additional sources: [American Psychiatric Association (2010)](https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Vagus Nerve Stimulation and Other Neuromodulation

<a id="topic-2.2.2.1.8-1"></a>

###### CANMAT guideline: VNS third-line, DBS investigational

> “To date, there are very few RCTs involving VNS, and these studies have failed to demonstrate the efficacy of VNS compared to sham control conditions in the short term.”
> “VNS is generally safe and well tolerated, with the most common side effects involving pain related to device implantation, voice hoarseness or alteration (due to intermittent stimulation of the larynx), coughing, headache, sore throat, and neck pain.”
> “Currently, VNS is the only surgical neuromodulation treatment approved for TRD by regulatory agencies and is recommended as a third-line option”
> “DBS and MST are currently considered investigational due to limited available evidence.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.8-2"></a>

###### VA/DoD guideline: against VNS and DBS outside research

> “For patients with MDD, we suggest against using vagus nerve stimulation outside of a research setting.”
> “(Weak against | Reviewed, Amended)”
> “Evidence indicates a greater than 5% chance of significant adverse events for patients who have been implanted with VNS.”
> “For patients with MDD, we recommend against using deep brain stimulation outside of a research setting.”
> “(Strong against | Reviewed, Not changed)”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.8-3"></a>

###### NICE interventional procedures guidance on implanted VNS

> “Evidence on the safety of implanted vagus nerve stimulation for treatment-resistant depression raises no major safety concerns, but there are frequent, well-recognised side effects.”
> “Evidence on its efficacy is limited in quality.”
> “Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.”

Source: [NICE (2020)](https://www.nice.org.uk/guidance/htg551/chapter/1-Recommendations)

<a id="topic-2.2.2.1.8-4"></a>

###### Medicare coverage of VNS limited to coverage with evidence development

> “Effective for services performed on or after February 15, 2019, the Centers for Medicare & Medicaid Services (CMS) will cover FDA-approved VNS devices for treatment resistant depression (TRD) through Coverage with Evidence Development (CED) when offered in a CMS-approved, double-blind, randomized, placebo-controlled trial with a follow-up duration of at least one year”
> “VNS is non-covered for the treatment of TRD when furnished outside of a CMS-approved CED study.”
> “All other indications of VNS for the treatment of depression are nationally non-covered.”

Source: [CMS vagus nerve stimulation national coverage determination (2019)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=230)

<a id="topic-2.2.2.1.8-5"></a>

###### RECOVER: 12-month sham-controlled trial

> “This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months.”
> “Percent time in MADRS response did not distinguish active from sham VNS.”
> “Active VNS exceeded sham VNS in rate of dyspnea (P = 0.035), a known side effect of VNS.”

Source: [Conway et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39706521/)

<a id="topic-2.2.2.1.8-6"></a>

###### RECOVER: quality of life and function

> “Active VNS was superior to sham in mean change in scores from baseline in the Mini-Q-LES-Q (P = 0.050) and WPAI item 6 (health condition's effect on regular activities [P = 0.050]) used as continuous variables, with a similar trend for Q-LES-Q (P = 0.061).”

Source: [Rush et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39701918/)

<a id="topic-2.2.2.1.8-7"></a>

###### RECOVER: durability of benefit over 24 months

> “Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025.”
> “Depressive symptom, daily function, and QoL benefits obtained after 12 months of adjunctive VNS were sustained in about 80% of participants continuing VNS.”
> “It did not demonstrate that VNS was necessary in achieving this sustained benefit.”
> “Conducting the study was also supported by the Centers for Medicare & Medicaid Services.”

Source: [Conway et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799215/)

<a id="topic-2.2.2.1.8-8"></a>

###### Five-year registry: adjunctive VNS compared with treatment as usual

> “This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients”
> “The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).”

Source: [Aaronson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28359201/)

<a id="topic-2.2.2.1.8-9"></a>

###### Deep brain stimulation of the ventral anterior limb of the internal capsule

> “Following the optimization phase, which lasted 51.6 (22.0) weeks, 10 patients (40%) were classified as responders and 15 individuals (60%) as nonresponders.”
> “During active DBS, patients scored significantly lower on the HAM-D-17 scale (13.6 [95% CI, 9.8-17.4]) than during sham DBS (23.1 [95% CI, 20.6-25.6]) (P < .001).”
> “Serious adverse events included severe nausea during surgery (1 patient), suicide attempt (4 patients), and suicidal ideation (2 patients).”

Source: [Bergfeld et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27049915/)

Additional sources: [Conway et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42642808/); [McAllister-Williams et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008595/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

In the Sequenced Treatment Alternatives to Relieve Depression trial, remission rates fell from 36.8% at step 1 to 13.0% at step 4, with higher relapse rates after more steps, and a reanalysis with the protocol-stipulated HRSD found a cumulative remission rate of 35.0% against the reported 67%. ICER's draft scope states that another antidepressant course succeeds much less often in TRD. Adjunctive atypical antipsychotics have a “greater side effect burden than antidepressant monotherapy”: one analysis reported akathisia with aripiprazole (NNH 4) and sedation with quetiapine (NNH 3), and one study found higher all-cause mortality with antipsychotic use (HR 1.21). Esketamine is dispensed and administered only in certified healthcare settings, with monitoring for at least 2 hours at each session, and ketamine and esketamine often require repeated visits for maintenance doses and have limited access in some regions. In one analysis, ketamine effects lasted no more than one week. After successful ECT, 51.1% of patients relapsed by 12 months on continuation pharmacotherapy, and ECT use is limited by stigma, general anaesthesia, and concern about cognitive effects. rTMS requires daily clinic visits, psychotherapy can be burdensome because of frequent visits, and access is limited because not all providers have adequate training, and VNS carries a greater than 5% chance of significant adverse events.

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/); [Pigott et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf); [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/); [Spielmans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3595214/); [Tsai et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40197402/); [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf); [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf); [Dean et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434915/); [Jelovac et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799066/)

<a id="topic-2.2.2.1.9-2"></a>

###### Diminishing remission with each successive treatment step

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.”
> “Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”
> “When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.2.1.9-3"></a>

###### Reanalysis of cumulative remission in the Sequenced Treatment Alternatives to Relieve Depression trial

> “In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria.”

Source: [Pigott et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/)

<a id="topic-2.2.2.1.9-4"></a>

###### Lower success of further antidepressant trials

> “The success of another course of antidepressant medications in TRD is much lower than in others with MDD; however, many patients with TRD are treated with additional trials of antidepressant medications.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.1.9-5"></a>

###### Tolerability of adjunctive antipsychotics

> “Adjunctive strategies, especially with atypical antipsychotic agents (serotonin and dopamine activity modulators), have greater evidence for efficacy and shorter time to response or remission, but they generally have a greater side effect burden than antidepressant monotherapy”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “However, antipsychotic users had increased risk of all-cause mortality (hazard ratio 1.21; 95% CI 1.07-1.33).”
> “These findings do not support the use of antipsychotic augmentation in patients with treatment-resistant depression.”

Source: [Tsai et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40197402/)

<a id="topic-2.2.2.1.9-6"></a>

###### Esketamine: certified settings and two-hour observation at each session

> “Healthcare settings must be certified in the program and ensure that SPRAVATO is: − Only dispensed and administered in healthcare settings.”
> “Because of the possibility of delayed or prolonged sedation, patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.9-7"></a>

###### Ketamine and esketamine: treatment space, repeated visits, and regional access

> “Additionally, there are unique resource and feasibility challenges associated with administering these treatments, such as the need for intravenous access with ketamine infusions and the need for appropriate clinical treatment space and post-treatment monitoring for both ketamine and esketamine.”
> “These resource challenges are compounded by the lack of long term durability from these treatments, which necessitates repeated trips to a treatment facility for receiving ongoing maintenance doses in many cases.”
> “There is currently limited access in some regions (e.g., rural areas) for both treatments due to a lack of providers with adequate clinical resources, experience, and training.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.9-8"></a>

###### Short duration of effect after ketamine

> “The effects of ketamine lasted no more than one week after treatment and clearly disappeared after two weeks.”

Source: [Dean et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434915/)

<a id="topic-2.2.2.1.9-9"></a>

###### ECT: stigma, anaesthesia, cognitive effects, and relapse

> “However, the clinical use of ECT is often hindered by stigma, the need for general anaesthesia, concern about cognitive adverse effects, and high rates of relapse after acute treatment.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “There is a large variation in preferences for using ECT due to both risks and stigma associated with the treatment.”
> “The Work Group noted that resources, acceptability, and feasibility sometimes limit the ability to use this treatment and that certain areas will not have this treatment option.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.9-10"></a>

###### Neuromodulation: availability, daily visits, and specialized personnel

> “because of feasibility issues, including limited availability (especially in the public health sector), patient burden (e.g., requiring daily clinic visits for rTMS), and the need for specialized personnel (e.g., anaesthesiologists for ECT).”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.9-11"></a>

###### VNS: surgical implantation and adverse events

> “Evidence indicates a greater than 5% chance of significant adverse events for patients who have been implanted with VNS.”
> “Acceptability, resource availability, and risk of surgical complications are also considerations.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

COMPASS has submitted a New Drug Application for COMP360 for TRD, which its press release defines as an inadequate response to two or more courses of antidepressants of adequate dose and duration. Guidelines that address psilocybin restrict it to research: the VA/DoD guideline recommends against psilocybin for MDD “outside of a research setting”, with very low confidence in the evidence; the CANMAT guideline update considers psilocybin-assisted psychotherapies “investigational treatments”; and a CANMAT task force recommends use primarily within clinical trials. The EMA guideline recommends starting psychedelic development in TRD and states that psychedelics need administration “in a controlled environment”. ICER's draft scope assesses psilocybin 25 mg in adults with MDD without psychotic features after two or more failed adequate antidepressant trials in the current episode, with esketamine, intravenous ketamine, and rTMS as comparators focusing on US outpatient settings. The company's November 2026 investor presentation states that dosing and monitoring will take place at a certified treatment center, and its quarterly release cites more than 8,500 treatment centers. The company described one or two initial administrations followed by episodic dosing per physician decision. Payer panel participants named head-to-head trials against esketamine or other active comparators as the most important evidence for coverage.

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx); [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf); [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/); [Rosenblat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720483/); [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-2.2.2.2-2"></a>

###### VA/DoD guideline: recommendation against psilocybin outside a research setting

> “Given the limited information on the safety and efficacy of psilocybin, MDMA, cannabis, and other unapproved pharmacologic treatments, we recommend against using these agents for MDD outside of a research setting.”
> “The Work Group’s confidence in the quality of the evidence was very low.”
> “Further, there are significant resource use and feasibility challenges to implementing psilocybin and MDMA treatments since dosing protocols to date have included prolonged therapeutic interventions and monitoring (between eight to 12 hours) following administration.”
> “There are also substantial pharmacy storage and dispensing implications, with both psilocybin and MDMA currently being classified as U.S. Drug Enforcement Agency (DEA) Schedule 1 compounds.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.2-3"></a>

###### CANMAT 2023 update: psilocybin-assisted psychotherapy considered investigational

> “Psychedelic-assisted psychotherapy was recently reviewed in a CANMAT Task Force Report.”
> “Although these results are promising, they are limited by ongoing methodological issues (e.g., lack of blinding, inadequate assessment of expectancy bias, heterogeneity of psychological support, and lack of long-term safety data).”
> “Hence, psilocybin- and other psychedelic-assisted psychotherapies are considered investigational treatments”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.2-4"></a>

###### CANMAT task force: psilocybin an experimental treatment for use within clinical trials

> “There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder.”
> “As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.”

Source: [Rosenblat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720483/)

<a id="topic-2.2.2.2-5"></a>

###### EMA depression guideline: psychedelic development in treatment-resistant depression and a controlled environment

> “Psychedelics are currently being recognised in psychiatry as potential treatment options to treat various medical conditions including MDD.”
> “Due to potential significant alterations of perception and behaviour, it is recommended to start development in a more severely affected population, such as patients with treatment resistant depression (section 4.4.1.).”
> “Therefore, psychedelics need to be administered in a controlled environment.”
> “The monotherapy setting with psychedelics alone may not be applicable or feasible.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.2-6"></a>

###### NICE guideline recommendations for treatment-resistant depression

> “See the NICE interventional procedures guidance on implanted vagus nerve stimulation for treatment-resistant depression.”
> “Esketamine nasal spray is not recommended in NICE technology appraisal guidance for treating treatment-resistant depression.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.2-7"></a>

###### ICER assessment scope: population, intervention, comparators, and setting

> “The population of focus for the review is adults ages 18 years and older with major depressive disorder, without psychotic features, and for whom two or more prior antidepressants prescribed at adequate dose and duration, during the current episode, have not resulted in adequate therapeutic benefit.”
> “Psilocybin (25 mg)”
> “Esketamine (SPRAVATO®, Janssen) / Intravenous (IV) ketamine, an anesthetic agent used off-label for TRD”
> “Repetitive Transcranial Magnetic Stimulation (rTMS)”
> “All relevant settings will be considered, with a focus on outpatient settings in the United States.”
> “Appropriate interventions in TRD include augmentation of medication therapy with an antipsychotic medication.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.2-8"></a>

###### Company statements on intended position in treatment-resistant depression

> “This 1-year data further supports the belief that, if approved, COMP360 could establish a new standard of care in TRD that can be life-changing for patients”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “we are confident that clinicians will adopt COMP360 as the treatment of choice for patients with TRD.”
> “Today, less than 3% of these patients are accessing the only marketed and approved TRD treatment, SPRAVATO, due largely to the burden associated with the required frequency of dosing.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.2-9"></a>

###### Anticipated dosing pattern: one or two initial administrations, then episodic retreatment

> “what we would envisage and target is after one or two initial administrations, that then there is the provision for episodic dosing per physician decision.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “We believe COMP360 has the potential to transform mental health care by moving beyond daily or frequent administration toward just a few treatments per year”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.2.2.2-10"></a>

###### Anticipated care setting: certified interventional psychiatry treatment centers

> “Patient self-administers oral capsule, monitored by a licensed HCP during session”
> “Dosing and monitoring to take place at a certified treatment center”
> “Well-established Infrastructure of Interventional Psychiatry Treatment Centers in Place and Preparing to Offer COMP360”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “COMP360 expected to fit seamlessly within an established and expanding infrastructure of more than 8,500 treatment centers”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “At launch, we will leverage the well-established interventional psychiatry treatment center infrastructure.”
> “These treatment sites are specifically designed to support in-office treatments for products that require multi-hour support and monitoring.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Our business and commercialization strategy for our investigational COMP360 psilocybin treatment depends on our ability to identify, qualify, prepare and support third-party treatment sites which will administer COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.2.2.2-11"></a>

###### Payer panel perspectives on the place of psilocybin in therapy

> “Perspectives among participants on the current evidence for psilocybin in TRD were mixed, with some indicating it is compelling or promising and their organization would likely cover upon FDA approval and others indicating it is uncertain or insufficient and would likely adopt a wait-and-see approach to coverage.”
> “These participants cited the lack of clinical treatment guidelines, comparative studies, and cost-effectiveness data as particular challenges when trying to determine the place in therapy of a new treatment and make coverage decisions.”
> “Participants indicated that the most important evidence required to support coverage of psilocybin would be head-to-head trials vs esketamine or other active comparators such as SGAs.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Intensity of the psychedelic experience and Week 3 response in the phase 2b trial

> “The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.”
> “At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.”
> “The existence of correlation does not establish causation and exploratory findings require further replication, preferably in larger independent samples.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

<a id="topic-2.2.2.3-2"></a>

###### Therapeutic alliance and Week 3 response in the phase 2b trial

> “Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).”
> “The effects of the alliance itself on therapeutic efficacy were either limited or absent.”

Source: [Goodwin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41881122/)

<a id="topic-2.2.2.3-3"></a>

###### Pretreatment clinical characteristics and the psychedelic experience

> “Dose was the strongest and most consistent predictor of the psychedelic experience.”
> “Positive affect, lower generalized anxiety symptoms, higher executive functioning, and greater personality disorder symptoms had significant effects on different aspects of the subjective psychedelic experience.”

Source: [Kirlić et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41362124/)

<a id="topic-2.2.2.3-4"></a>

###### Antidepressant discontinuation before dosing

> “Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.”
> “Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

> “No significant differences were found between medication discontinued (n = 18) and unmedicated at screening (UAS) (n = 9) groups in clinician rated depression (p = 0.759), self-reported depression (p = 0.215), anxiety (p = 0.178), and suicidality (p = 0.882) symptoms over time, with both groups having clinically significant benefits on all outcomes assessed.”

Source: [Chisamore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11948223/)

<a id="topic-2.2.2.3-5"></a>

###### Concomitant SSRI treatment in an open-label adjunctive study

> “in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).”
> “Future research should examine whether the outcomes of psilocybin as a monotherapy or as an adjunct to SSRIs remain comparable in a longer term follow up.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-2.2.2.3-6"></a>

###### Severe treatment resistance and comorbid PTSD in an open-label single-site study

> “Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD).”
> “Depressive symptoms were significantly decreased at week 3 (MADRS least-squares mean change=-15.8, 95% CI=-25.4 to -6.3) and Week 12 (MADRS least-squares mean change=-17.2, 95% CI=-25.2 to -9.1).”
> “In exploratory analyses, the Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antidepressant responses.”
> “Patients with comorbid PTSD (N=5) showed significantly less antidepressant effect of psilocybin.”

Source: [Aaronson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741440/)

<a id="topic-2.2.2.3-7"></a>

###### Veterans with severe treatment resistance in the same open-label study

> “Of 15 participants, 60 % met response and 53 % met remission criteria at Week 3.”
> “Co-morbid PTSD did not significantly influence study outcomes.”
> “The psychedelic experience reported in 5D-ASC did not correlate with response.”

Source: [Ellis et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39343309/)

<a id="topic-2.2.2.3-8"></a>

###### Number of prior treatment failures: company statements

> “We haven't yet done an analysis of the response or remission rates or other outcome measures based upon the number of lines of treatment that have failed these patients within our studies.”
> “because we were studying treatment-resistant depression, we were required to study failures after two failures. We would not have any data on the zero to two failures.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.3-9"></a>

###### Early prediction of response from language in the post-dosing session

> “While the phase-IIb results are promising, the treatment works for a portion of the population and early prediction of outcome is a key objective as it would allow early identification of those likely to require alternative treatment.”
> “Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12.”
> “Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="topic-2.2.2.3-10"></a>

###### Control-group response in psilocybin trials compared with SSRI and esketamine trials

> “MADRS response rates for control treatments in SSRI trials were 14 percentage points higher than in psilocybin trials and in esketamine trials were 23 percentage points higher than in psilocybin trials.”
> “The poor control treatment outcomes in psilocybin trials suggest that it may not be as broadly effective for depression as estimated.”

Source: [Hieronymus et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311713/)

> “However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

<a id="topic-2.2.2.3-11"></a>

###### Trial methodology and study size as moderators in meta-analyses

> “The subgroup analyses found larger effects, albeit non-significant differences in subgroup heterogeneity, associated with studies that administered psilocybin in bodyweight-adjusted doses and provided longer preparation, dosing, and integration sessions and provided non-manualized psychotherapy.”

Source: [Syed et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41587629/)

> “Effects were moderate and attenuated in larger and better-controlled studies.”

Source: [Borgogna et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449434/)

<a id="topic-2.2.2.3-12"></a>

###### Dose-response by type of depression

> “The determined 95% effective doses per day (ED95) were 8.92, 24.68, and 36.08 mg/70 kg for patients with secondary depression, primary depression, and both subgroups, respectively.”

Source: [Perez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37557019/)

<a id="topic-2.2.2.3-13"></a>

###### Regulatory expectations for characterizing variability in response

> “In particular, the relationship between characteristics of the acute psychedelic experience and clinical improvement, as well as the need for dose adjustments should be investigated.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.3-14"></a>

###### Subgroups planned in the ICER assessment

> “As data permit, we will also plan to examine subgroups of patients suggested by patients and clinical experts.”
> “Age (e.g., 18-64 vs. ≥ 65 years of age)”
> “Number of prior antidepressant trials (e.g., two, three, four)”
> “Concomitant use of medication for mental health (e.g., antidepressants, antipsychotics)”
> “Prior exposure to psychedelics”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.3-15"></a>

###### Payer requests for subgroup data

> “Other data participants saw as important included subgroup analyses to elucidate the appropriate treatment population and potential budget impact, and data to assess cost-effectiveness.”
> “They also highlighted that treatment effect is likely more variable given the nature of the treatment and additional, longer-term data will be necessary to increase the predictability of response.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### FDA direction to use the Spravato REMS as a template

> “the FDA directed us to use the SPRAVATO REMS as a template”
> “we expect there to be training content within the REMS that will take about one to two hours to review.”
> “From a site side, this will be very consistent with what they are already doing for SPRAVATO, outside of a couple of small tweaks that would be specific to the molecule itself, like the six hours versus two hours requirement.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “For instance, we believe that COMP360, if approved, would be subject to a REMS program, under the applicable FDA regulations.”
> “REMS programs are costly and time-consuming for providers to comply with, involving high administrative burden, which could delay or limit our ability to commercialize our investigational COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.2.2.4-2"></a>

###### Spravato REMS requirements named as the template

> “Healthcare settings must be certified in the program and ensure that SPRAVATO is:”
> “Only dispensed and administered in healthcare settings.”
> “Patients treated in outpatient settings (e.g. medical offices and clinics) must be enrolled in the program.”
> “Administered by patients under the direct observation of a healthcare provider and that patients are monitored by a healthcare provider for at least 2 hours after administration of SPRAVATO”
> “Pharmacies must be certified in the REMS and must only dispense SPRAVATO to healthcare settings that are certified in the program.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.4-3"></a>

###### Session monitoring: FDA guidance and company plans

> “Observation by two monitors for the duration of the treatment session.”
> “A health care provider with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently, serving as the lead monitor.”
> “An assistant monitor with a nursing or bachelor’s degree and at least 1 year of clinical experience in a licensed mental health care setting.”
> “If the lead monitor is not a physician, availability of a licensed on-call physician able to reach the clinical site within 15 minutes in the event of a medical emergency.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “our design matches what they have guided, which is to have one primary monitor and to use CCTV to assist with the total monitoring by two total healthcare providers.”
> “we would certainly anticipate that the final requirements will be no more stringent than what has been required so far in clinical trials.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.4-4"></a>

###### FDA guidance on postmarketing risk mitigation and the psychotherapy component

> “Sponsors should consider the potential need for a risk evaluation and mitigation strategy or additional safety studies that may be required in the postmarketing setting when preparing and submitting a marketing application.”
> “As of the publication date of this guidance, the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.4-5"></a>

###### Three-phase psychological support model used in COMP360 trials

> “Our trial protocols provide that such support is delivered over three different phases: preparation, the COMP360 administration session, and post-administration follow-up.”
> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”
> “After the acute effects of psilocybin subside, patients are evaluated for safety and discharged.”
> “In our clinical trials, healthcare professionals refrain from intervening with the patient’s experience, unless required for safety reasons.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery.”

Source: [Kirlić et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741434/)

> “Training consists of four components: an online learning platform; in-person training; applied clinical training; and ongoing individual mentoring and participation in webinars.”
> “As part of the phase IIb study of psilocybin therapy for treatment-resistant depression, 65 health care professionals have been fully trained as therapists and assisting therapists, across the US, Canada and Europe.”

Source: [Tai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908919/)

<a id="topic-2.2.2.4-6"></a>

###### Non-directive support during the administration session

> “Speech by either party during the administration sessions was rare; on average, 78% of the time was filled with silence, compared to 25% to 30% in non-administration sessions.”

Source: [Dougherty et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42460632/)

> “It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy.”
> “Support strategies include breath and body awareness, short verbal cues, and physical proximity.”

Source: [COMPASS Pathways support model publication release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx)

> “Extrapolation from the trial setting to clinical practice or the plan to provide specific training to therapists needs to be addressed.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.4-7"></a>

###### Company site-readiness and patient support programs

> “At approval, focus will be on site preparedness – including training, education, REMS certification, assistance with reimbursement and patient support”

Source: [COMPASS Pathways second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)

> “We will also have a dedicated team of specialists working directly with clinics to facilitate the logistics associated with reimbursement for both the drug and the monitoring time for COMP360 administration.”
> “we will have patient support programs in place to ensure that affordability is not a barrier to access in the early days of the launch.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.4-8"></a>

###### Payer coverage criteria and reauthorization proposed for psilocybin

> “All payer participants agreed that coverage criteria would align with the FDA-approved product label including, for instance, the quantity and frequency of treatment, and would comply with the REMS requirements.”
> “Several added they would look to previous experience with esketamine for guidance and that coverage criteria for psilocybin may be similar.”
> “Whereas some participants would accept provider attestation for continuation of therapy, others would require documentation of improvement and sustained treatment response.”
> “One PBM participant suggested that reviewing claims for other TRD treatments subsequent to psilocybin administration could further support determination of treatment response.”
> “Participants discussed reimbursement considerations with coverage of psilocybin including developing a bundled payment model combining all related services (eg, medication, administration, psychotherapy) into a single billable episode of care”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-2.2.2.4-9"></a>

###### Network adequacy and workforce

> “Participants identified the shortage of qualified mental health professionals, both in general and as part of their organizations’ networks, as a primary challenge with equitable access to psilocybin treatment and post-treatment care.”
> “Participants expressed concern related to the potential requirements for equitable access to specialized administration sites because the number of these may be limited, especially in rural areas.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-2.2.2.4-10"></a>

###### State-licensed psilocybin services in Oregon as a delivery analog

> “The MCAP Psilocybin Program implements Ballot Measure 109 (now codified as ORS 475A), which was passed in November 2020 and directs the Oregon Health Authority to license and regulate the manufacturing, transportation, delivery, sale, and purchase of psilocybin products and the provision of psilocybin services.”

Source: [Oregon Health Authority](https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx)

> “Results indicated that in the 16 active training programs, the mean tuition was $9,359 and half offered diversity scholarships.”
> “The mean planned price for a session was $1,388 and the most common areas of specialization were trauma, mental disorders, consciousness exploration, and spirituality.”

Source: [Luoma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12304229/)

<a id="topic-2.2.2.4-11"></a>

###### Psychological support delivery in a publicly funded health service

> “Oral psychedelics such as psilocybin have an acute effect evolving over 6-8 h and are generally given in combination with psychological support.”
> “In this feature, we discuss these issues and outline a model for psychological support delivery in publicly funded health services such as the National Health Service.”

Source: [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41906234/)

<a id="topic-2.2.2.4-12"></a>

###### Measurement-based care in major depression

> “Significantly more patients in the measurement-based care group than in the standard treatment group achieved response (86.9% compared with 62.7%) and remission (73.8% compared with 28.8%).”

Source: [Guo et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26315978/)

<a id="topic-2.2.2.4-13"></a>

###### Executive Order 14401: Right to Try access and federal-state programs

> “The FDA and Drug Enforcement Administration shall facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act (21 U.S.C. 360bbb-0a)”
> “allocate at least $50 million from existing funds to support and partner with State governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses”

Source: [White House (2026)](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/)

Additional sources: [Goodwin et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37434509/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Pooled effect of psilocybin-assisted therapy in meta-analyses of randomized trials

> “The pooled SMD for 1-week between-group change in depression ratings was -0.72 [95% CI, -0.95 to -0.49; I2 = 17%; 5 RCTs; n = 403], favouring PAT; results were similar at days 2, 14, and 42.”
> “The response [RR = 3.42; 95% CI, 2.35-4.97; I2 = 0%; 4 RCTs; n = 373] and remission [RR = 3.66; 95% CI, 2.26-5.92; I2 = 0%; 4 RCTs; n = 373] rates also favored PAT.”

Source: [Menon et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39627679/)

> “The meta-analysis included 9 studies (pooled n = 596) and yielded a large effect size in favour of psilocybin (SMD = -0.78; p<0.001).”

Source: [Haikazian et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37844352/)

> “In major depressive disorder (MDD), psilocybin/ayahuasca/LSD reduced depressive symptoms (k = 8; SMD=-0.62 [-0.97; -0.28]; I2=55 %; GRADE=very low).”

Source: [Højlund et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41205366/)

<a id="topic-2.2.2.7-2"></a>

###### Within-group change in psilocybin, SSRI, and esketamine trials

> “Pretreatment to posttreatment SMCs (SEMs) were 1.21 (0.15) for psilocybin, 1.28 (0.06) for SSRIs, and 1.43 (0.15) for esketamine and were 0.50 (0.15), 1.00 (0.08), and 1.12 (0.17) for their respective control treatments.”

Source: [Hieronymus et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311713/)

<a id="topic-2.2.2.7-3"></a>

###### Relative effect compared with escitalopram in a network meta-analysis

> “The relative effect of high dose psilocybin was larger than escitalopram at 10 mg (4.66 (95% credible interval 1.36 to 7.74)) and 20 mg (4.69 (1.64 to 7.54)).”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

<a id="topic-2.2.2.7-4"></a>

###### Phase 2b trial: response, remission, and sustained response after a single 25 mg dose

> “In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.”
> “Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-2.2.2.7-5"></a>

###### Durability after a single dose over 52 weeks

> “For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-2.2.2.7-6"></a>

###### Company-reported response, remission, and durability with retreatment

> “for all participants in Part C who received a 25 mg dose, strong response and remission rates were observed with 40%-45% responders and approximately 30% remitters across all timepoints in the 6 weeks post the Part C dose”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Remarkable durability sustained through at least 6 months with only 1 or 2 additional doses after initial dose”
> “39% of participants in 25mg arm achieved a clinically meaningful reduction in MADRS at Week 6”
> “Clinically meaningful reduction in MADRS defined as a >25% reduction from baseline in MADRS total score at Week 6”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.2.2.7-7"></a>

###### Independent phase 2b trial in treatment-resistant depression with an active placebo

> “Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide.”
> “In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome.”

Source: [Mertens et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13000742/)

<a id="topic-2.2.2.7-8"></a>

###### Real-world outcomes outside controlled trials

> “Response and remission rates were 33.3% and 22.2% (MADRS), and 27.8% and 27.8% (BDI).”
> “Psilocybin was associated with a clinically meaningful reduction in depressive symptoms, with response and remission rates below those reported in previous trials.”

Source: [Jungwirth et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453954/)

<a id="topic-2.2.2.7-9"></a>

###### Long-term outcomes in veterans with severe treatment resistance

> “At Month 12, 40 % maintained response and 30 % maintained remission.”
> “However, the antidepressant effects began to wane at 6 months, and then more substantially after 9 months, although these increases in MADRS did not reach statistical significance.”

Source: [Ellis et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40499827/)

<a id="topic-2.2.2.7-10"></a>

###### Regulatory statement on the evidence for durability and retreatment

> “Endurance of effect needs to be demonstrated.”
> “The experience and the available information on the sustainability of the action and the long-term effects, both desirable and undesirable of psychedelics and the efficacy of re-treatment are very limited.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.7-11"></a>

###### Expected outcomes with further conventional treatment steps or usual care

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.”
> “Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

> “The 12- and 24-month IDS-SR-30 response rates were 11.6% (13/112) and 18.4% (19/103), respectively.”
> “The 12- and 24-month IDS-SR-30 remission rates were 3.6% (4/112) and 7.8% (8/103), respectively.”

Source: [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/)

> “In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission.”

Source: [Fekadu et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19007996/)

> “The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).”

Source: [Aaronson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28359201/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
